

*Handwritten signature/initials*

CANNABINOID RECEPTOR LIGANDS

BACKGROUND OF THE INVENTION


This invention relates to cannabinoid receptor ligands and, more particularly, to compounds that bind to cannabinoid (CB<sub>2</sub>) receptors. Compounds according to the present invention generally exhibit anti-inflammatory and immunomodulatory activity and are useful in treating conditions characterized by inflammation and immunomodulatory irregularities. Examples of conditions which may be treated include, but are not limited to, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, multiple sclerosis, diabetes, cancer, glaucoma, osteoporosis, renal ischemia, cerebral stroke, cerebral ischemia, and nephritis. The invention also relates to pharmaceutical compositions containing said compounds.

Cannabinoid receptors belong to the superfamily of G-protein coupled receptors. They are classified into the predominantly neuronal CB<sub>1</sub> receptors and the predominantly peripheral CB<sub>2</sub> receptors. While the effects of CB<sub>1</sub> receptors are principally associated with the central nervous system, CB<sub>2</sub> receptors are believed to have peripheral effects related to bronchial constriction, immunomodulation and inflammation. As such, a selective CB<sub>2</sub> receptor binding agent is expected to have therapeutic utility in the control of diseases associated with inflammation, immunomodulation and bronchial constriction such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, diabetes, osteoporosis, renal ischemia, cerebral stroke, cerebral ischemia, nephritis, inflammatory disorders of the lungs and gastrointestinal tract, and respiratory tract disorders such as reversible airway obstruction, chronic asthma and bronchitis (see, e.g., R.G. Pertwee, Curr. Med. Chem. 6(8), (1999), 635).

Various compounds have reportedly been developed which interact with CB<sub>2</sub> receptors and/or which have, *inter alia*, anti-inflammatory activity associated with cannabinoid receptors. See, e.g., U.S. Pat. Nos. 5,338,753, 5,462,960, 5,532,237, 5,925,768, 5,948,777, 5,990,170, 6,013,648 and 6,017,919.

# SUMMARY OF THE INVENTION

This invention relates to compounds of formula I:



- 5 a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein:

$R^1$  is H, alkyl, haloC<sub>1</sub>-C<sub>6</sub> alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, N(R<sup>2</sup>)<sub>2</sub>, or NR<sup>2</sup>aryl, unsubstituted aryl or aryl substituted with one to three X;

$R^2$  is the same or different in each occurrence and is independently selected from H or C<sub>1</sub>-C<sub>6</sub> alkyl;


$R^3$  is H, C<sub>1</sub>-C<sub>6</sub> alkyl, Cl, F, CF<sub>3</sub>, OCF<sub>2</sub>H, OCF<sub>3</sub>, OH or C<sub>1</sub>-C<sub>6</sub> alkoxy;


- 15  $R^4$  is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, cycloalkyl, alkenyl, aryl, benzyl, heteroaryl, heterocycloalkyl, arylNH-, heteroarylNH-, cycloalkylNH-, N(R<sup>2</sup>)<sub>2</sub>, or NR<sup>2</sup>aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, phenyl or heteroaryl optionally substituted with one to three X;

$R^5$  is H or C<sub>1</sub>-C<sub>6</sub> alkyl;


$R^6$  is H or C<sub>1</sub>-C<sub>6</sub> alkyl; or


- 20  $R^5$  and  $R^6$  taken together with the carbon atom form a carbonyl group;

$L^1$  is C<sub>1</sub>-C<sub>6</sub> alkylene, C<sub>2</sub>-C<sub>6</sub> alkenylene, C(R<sup>2</sup>)<sub>2</sub>, , -CHOR<sup>2</sup>-, NOR<sup>5</sup>-, -SO<sub>2</sub>-, -SO-, -S-, -O-, -NR<sup>2</sup>-, -C(O)NR<sup>2</sup>-, -NR<sup>2</sup>C(O)-, -CHCF<sub>3</sub>- or -CF<sub>2</sub>-;

$L^2$  is a covalent bond,  $C_1-C_6$  alkylene,  $-C(R^2)_2-$ , ,  $-CHOR^2-$ ,  $-C(R^2)OH$ ,  $NOR^5-$ ,  $-SO_2-$ ,  $-NR^2SO_2-$ ,  $-SO-$ ,  $-S-$ ,  $-O-$ ,  $-SO_2NR^2-$ ,  $-N(R^2)-$ ,  $-\bar{C}(O)NR^2-$  or  $-NR^2C(O)-$ ;

X is the same or different, and is independently selected from H, halogen,  $CF_3$ , CN,  $OCF_2H$ ,  $OCF_2CF_3$ ,  $OCF_3$ ,  $OR^2$ ,  $C_1-C_6$  alkyl, cycloalkyl, cycloalkoxy,  $C_1-C_6$  alkoxy, 5 alkoxy $C_1-C_6$  alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, - $OSO_2R^2$ ,  $-COOR^2$ ,  $-CON(R^2)_2$ ,  $NHR^2$ ,  $arylNH-$ ,  $N(R^2)_2$ , or  $NR^2$  aryl;

Y is a covalent bond,  $-CH_2-$ ,  $-SO_2-$ , or ;

Z is a covalent bond,  $-CH_2-$ ,  $-SO_2-$  or ; or

Y,  $R^1$ , Z and  $R^2$  can be taken together with the nitrogen atom to form a 10 heterocycloalkyl; with the proviso that if Y is a covalent bond,  $R^1$  cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4.

Cannabinoid receptor ligands according to the present invention have anti- 15 inflammatory activity and/or immunomodulatory activity and are useful in the treatment of various medical conditions including, e.g., cutaneous T cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing aveolitis, 20 psoriasis, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn's disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD) or bronchitis. It is contemplated that a compound of this invention may be useful in treating more than one of the diseases listed.

25 Additionally, a compound of the present invention may be co-administered or used in combination with disease-modifying antirheumatic drugs (DMARDS) such as methotrexate, azathioprine, leflunomide, penicillamine, gold salts, mycophenolate mofetil, cyclophosphamide and other similar drugs. They may also be co-administered with or used in combination with NSAIDS such as piroxicam, naproxen,

Sub  
C1

indomethacin, ibuprofen and the like; COX-2 selective inhibitors such as Vioxx® and Celebrex®; COX-1 inhibitors such as Feldene; immunosuppressives such as steroids, cyclosporine, Tacrolimus, rapamycin, muromonab-CD3 (OKT3), Basiliximab and the like; biological response modifiers (BRMs) such as Enbrel, Remicade, IL-1

5 antagonists, anti-CD40, anti-CD28, IL-10, anti-adhesion molecules and the like; and other anti-inflammatory agents such as p38 kinase inhibitors, PDE4 inhibitors, TACE inhibitors, chemokine receptor antagonists, Thalidomide and other small molecule inhibitors of pro-inflammatory cytokine production. They may also be co-administered with or used in combination with H1 antagonists such as Claritin, Clarinex, Zyrtec, 10 Allegra, Benadryl, and other H1 antagonists. Other drugs that the compounds of the invention may be co-administered or used in combination with include Anaprox, Arava, Arthrotec, Azulfidine, Aspirin, Cataflam, Celestone Soluspan, Clinoril, Cortone Acetate, Cuprimine, Daypro, Decadron, Depen, Depo-Medrol, Disalcid, Dolobid, Naprosyn, Gengraf, Hydrocortone, Imuran, Indocin, Lodine, Motrin, Myochrysine, 15 Nalfon, Naprelan, Neoral, Orudis, Oruvail, Pediapred, Plaquenil, Prelone, Relafen, Solu-Medrol, Tolectin, Trilisate and Volataren. These include any formulations of the above-named drugs.

For the treatment of multiple sclerosis, the compounds of the invention may be co-administered or used in combination with Avonex, Betaseron, Rebif and Copaxone.

20 These include any formulations of the above-named drugs.

For the treatment of psoriasis, the compounds of the invention may be co-administered or used in combination with steroids, methotrexate, cyclosporin, Xanelin, Amivere, Vitamin D analogs, topical retinoids, anti-TNF- $\alpha$  compounds and other drugs indicated for this condition. These include any formulations of the above-named

25 drugs.

For the treatment of asthma, the compounds of the invention may be co-administered or used in combination with Singulair, Accolate, Albuterol, and other drugs indicated for this disease. These include any formulations of the above-named drugs.

30 For the treatment of inflammatory bowel disease or Crohn's disease, the compounds of the invention may be co-administered or used in combination with sulfasalazine, budesonide, mesalamine and other drugs indicated for these diseases. These include any formulations of the above-named drugs.

In another aspect, the invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I in a pharmaceutically acceptable carrier.

#### DETAILED DESCRIPTION

5 Unless otherwise defined, the following definitions shall apply throughout the specification and claims.

When any variable (e.g.,  $R^2$ ) occurs more than one time in any constituent, its definition in each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such  
10 combinations result in stable compounds.

"Alkyl" means straight or branched alkyl chains of 1 to 12 carbon atoms. The term includes the isomers thereof such as isopropyl, isobutyl, sec-butyl, etc.

"Haloalkyl" means alkyl having 1 or more halo atoms.

"Heteroalkyl" means straight or branched alkyl chain comprised of from 1 to 12  
15 carbon atoms and 1 or more heteroatoms independently selected from the group consisting of N, O and S.

"Cycloalkyl" as used herein refers to an aliphatic ring system having 3 to 10 carbon atoms and 1 to 3 rings, including, but not limited to cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, and adamantyl among others.

20 "Heterocycloalkyl" means cycloalkyl containing one or more heteroatoms.

"Aryl" means an aromatic monocyclic or multicyclic ring system comprising from 6 to 14 carbon atoms. Non-limiting examples include phenyl, naphthyl, indenyl, tetrahydronaphthyl and indanyl.

"Arylalkyl" means a group in which the aryl and alkyl are as previously  
25 described. Non-limiting examples of suitable arylalkyl groups include benzyl, 2-phenethyl and naphthlenylmethyl. The bond to the parent moiety is through the alkyl.

"Heteroaryl" means a single ring or benzofused heteroaromatic group of 5 to 10 atoms comprised of 1 to 9 carbon atoms and 1 or more heteroatoms independently selected from the group consisting of N, O and S. N-oxides of the ring nitrogens are  
30 also included, as well as compounds wherein a ring nitrogen is substituted by a  $C_1$ - $C_6$  alkyl group to form a quaternary amine. Examples of single-ring heteroaryl groups are pyridyl, oxazolyl, isoxazolyl, oxadiazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl,

tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazinyl, pyrimidyl, pyridazinyl and triazolyl. Examples of benzofused heteroaryl groups are indolyl, quinolyl, isoquinolyl, phthalazinyl, benzothienyl (i.e., thionaphthenyl), benzimidazolyl, benzofuranyl, benzoxazolyl and benzofurazanyl. All positional isomers are contemplated, e.g., 2-pyridyl, 3-pyridyl and 4-pyridyl.

"Alkoxy" means an alkyl radical attached by an oxygen, i.e., alkoxy groups having 1 to 9 carbon atoms.

"Alkenyl" means straight or branched chains of carbon atoms having one or more double bonds in the chain, conjugated or unconjugated.

"Oxime" means a  $\text{CH}(\text{:NOH})$  radical containing moiety.

"Halogen", "halogenated" or "halo" refers to fluorine, chlorine, bromine or iodine radicals.

The term "prodrug," as used herein, represents compounds which are rapidly transformed in vivo to the parent compound of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.

Linker groups such as  $\text{L}^1$ ,  $\text{L}^2$ , Y and Z are divalent.

In a preferred group of compounds of formula I,

$\text{L}^1$  is  $-\text{SO}_2-$ ,  $-\text{CH}_2-$ ,  $-\text{CHCH}_3-$ ,  $-\text{C}(=\text{O})-$ ,  $-\text{C}(\text{NO})-$ ,  $-\text{C}(\text{NO})\text{R}^2-$ ,  $-\text{C}(\text{CH}_3)_2-$ ,  $-\text{CHOH}-$ ,  $-\text{O}-$ ,  $-\text{S}-$  or  $-\text{S}=\text{O}-$ ;

$\text{L}^2$  is  $-\text{SO}_2-$ ,  $-\text{C}(=\text{O})-$ ,  $-\text{CH}_2-$ ,  $-\text{CH}(\text{CH}_3)-$ ,  $-\text{C}(\text{CH}_3)_2-$ ,  $-\text{C}(\text{CH}_3)=\text{CH}_2-$ ,  $-\text{NH}-$ ,  $-\text{O}-$ ,  $-\text{NHSO}_2-$ ,  $-\text{NHC}(\text{O})-$  or  $-\text{C}(\text{CH}_3)(\text{OH})-$ ;

$\text{R}^1$  is H,  $-\text{CH}_3\text{NH}_2$ ,  $-\text{CH}_2\text{CF}_3$ ,  $-\text{NHC}_3\text{H}_7$ ,  $-\text{NHC}_2\text{H}_6$ ,  $-\text{NHC}_4\text{H}_9$ ,  $\text{C}_1$ - $\text{C}_6$  alkyl,  $-\text{CF}_3$ ,  $-\text{CH}(\text{CH}_3)_2$ , thiophenyl, morpholinyl, cyclopropanyl, benzyl, naphthyl,  $\text{C}(\text{CH}_3)_3$ , NHphenyl, 3,5-difluorophenyl, phenyl, N-cyclopentyl or  $\text{N}(\text{CH}_3)_2$ ;

$R^2$  is H or  $CH_3$ ;

$R^4$  is furanyl, pyridyl, pyrimidyl, thiophenyl, quinolyl, t-butoxy, alkoxy, cyclohexyl, phenyl, tolyl,  $C_3H_7$ , dimethylpyrimidyl, trifluoromethoxyphenyl, morpholinylphenyl or  $CH_3$ ; with the proviso that when  $R^4$  is t-butoxy,  $L^2$  must be

5  $-CH_2-$ ,  $-CHCH_3-$ ,  $-C(CH_3)_2-$  or  $-C=CH_2-$  all of the above optionally substituted with one to three substituents, which are the same or different and are independently selected from X;

$R^5$  and  $R^6$  are independently H or  $CH_3$ ;

X is H, Cl,  $CF_3$ ,  $OCH_3$ ,  $OCF_3$ ,  $OCF_2H$ ,  $CH_3$  or  $C_1-C_6$  cycloalkyl;

10 Y is  $-SO_2-$  or  $-C=O-$ ;  
Z is a covalent bond; or

$R^1$ , Y,  $R^2$  and Z taken together with the nitrogen atom form a morpholinyl group.

15 In a more preferred embodiment of the invention,

$L^1$  is  $-SO_2-$  or  $-CH_2-$ ;

$L^2$  is  $-SO_2-$ ;

$R^1$  is  $CH_3$  or  $CF_3$ ; and

20  $R^4$  is phenyl, pyrimidyl or pyridyl, said phenyl, pyrimidyl or pyridyl groups optionally substituted with one to three substituents independently selected from the group consisting of  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, OH,  $CF_3$  and halogen.

More preferably, the phenyl is substituted with  $OCH_3$  or halogen selected from fluorine and chlorine.

25

Compounds of the invention may have at least one asymmetrical carbon atom and therefore all isomers, including diastereomers and rotational isomers are contemplated as being part of this invention. The invention includes (+)- and (-)- isomers in both pure form and in admixture, including racemic mixtures. Isomers can  
30 be prepared using conventional techniques, either by reacting optionally pure or optically enriched starting materials or by separating isomers of a compound of

formula I. Those skilled in the art will appreciate that for some compounds of formula I, one isomer may show greater pharmacological activity than other isomers.

Compounds of formula I can exist in unsolvated and solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable  
5 solvents such as water, ethanol and the like, are equivalent to the unsolvated forms for purposes of this invention.

Compounds of the invention with a basic group can form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic,  
10 malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those in the art. The salt is prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt. The free base form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium bicarbonate. The free base form differs from  
15 its respective salt form somewhat in certain physical properties, such as solubility in polar solvents, but the salt is otherwise equivalent to its respective free base forms for purposes of the invention.

Certain compounds of the invention are acidic (e.g., compounds where  $R^2$  is a hydrogen covalently bonded to N). Acidic compounds according to the present  
20 invention can form pharmaceutically acceptable salts with inorganic and organic bases. Examples of such salts are the sodium, potassium, calcium, aluminum, magnesium, zinc, lithium, gold and silver salts. Also included are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine, piperazines and other amines.

25 Compounds of the present invention are generally prepared by processes known in the art, for example by the processes described below.

The following abbreviations are used in the procedures and schemes: aqueous (aq), anhydrous (anhyd), n-butyllithium (n-BuLi), dibromodimethylhydantoin (DBDMH), diisopropylethylamine (DIPEA), diethyl ether ( $Et_2O$ ), dimethylacetamide (DMA),  
30 dimethyl sulfoxide (DMSO), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), ethanol (EtOH), ethyl acetate (EtOAc), 2-propanol (IPA), leaving group (LG), lithium hexamethyldisilazide (LHMDS), meta-chloroperoxybenzoic acid (MCPBA), methanesulfonic acid (MsOH), methanesulfonyl chloride (MsCl),




N-iodosuccinamide (NIS), preparative thin layer chromatography on Merck- silica plates (PTLC), phenyl (Ph), pyridinium chlorochromate (PCC), pyridine (Py), trifluoroacetic anhydride (TFAA), triflic anhydride (Tf<sub>2</sub>O), tetrahydrofuran (THF), silica gel chromatography (sgc), thin layer chromatography (TLC), room temperature (rt), 5 hours (h), minutes (min), molar (M), pounds per square inch (psi), and saturated aqueous sodium chloride solution (brine).

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215

## General Scheme I Preparation of Aryl-Bis-Sulfone Compounds

Reaction Conditions are shown to the left of all vertical and angled arrows.



### Description of Reactions-General Scheme I

In step 1, trifluoroacetic anhydride is dissolved in a suitable inert solvent such as methylene chloride and reacted with a benzyl amine at room temperature for 1-5 hr. MsOH (2 eq) is added followed by DBDMH and the reaction mixture is stirred

overnight at room temperature and subjected to aqueous work up. The crude product is recrystallized from a mixture of Et<sub>2</sub>O and hexanes or purified via chromatography.

5 In step 2, the product of step 1 is dissolved in THF, cooled in a dry ice/IPA bath and treated with methyllithium then n-BuLi. The resulting dianion may be trapped with a sulfonyl fluoride or a disulfide. If a disulfide is the trapping agent, the resulting product is oxidized with MCPBA in CH<sub>2</sub>Cl<sub>2</sub> at room temperature for 1-6 h. The product may be purified via chromatography or crystallization.

In step 3, the product of step 2 is dissolved in THF and treated with n-BuLi at -78 °C to form a dianion that is trapped with a suitable electrophile.

10 Alternatively, in step 3 the product of step 2 is dissolved in THF treated with n-BuLi at -78 °C to form a dianion which is trapped with iodine to provide the iodo substituted product. The product may be purified via sgc or crystallization. The iodo product can be converted to a similar product by nucleophilic aromatic substitution with a variety of nucleophiles, including amines, alcohols, and thiols.


15 In step 4, the product of step 3 is dissolved in a suitable solvent such as dioxane, ethanol, methanol or THF and an alkali metal hydroxide or carbonate such as lithium hydroxide or potassium carbonate is added either as an aqueous solution or as a solid. The reaction mixture is stirred at room temperature for 0.5-24 h. The product may be purified via sgc or crystallization.

20 In step 5, a combination of the product of step 4 and a tertiary amine base was dissolved in a suitable solvent such as CH<sub>2</sub>Cl<sub>2</sub> or dioxane, at room temperature, cooled, and a suitable electrophile is added. The reaction mixture is stirred between -78 °C and 100 °C for 0.5 to 48 h. The product may be purified via sgc or crystallization.

25 In step 6, the product of step 5 is dissolved in a suitable inert solvent such as THF or CH<sub>2</sub>Cl<sub>2</sub> and treated with a suitable base such as NaH or triethylamine. An electrophile is added and the reaction mixture is stirred between 0 °C and 100°C for 0.5 to 48 h. The product may be purified via sgc or crystallization.

## General Scheme II

### Preparation of Methylene Linked Compounds



### Description of reactions-General Scheme II

In step 1, trifluoroacetic anhydride is dissolved in a suitable inert solvent such as methylene chloride and treated with a benzyl amine at ambient temperature, then stirred for 1-5 h. Methanesulfonic acid (2 eq) is added followed by dibromodimethylhydantoin and the reaction mixture is stirred overnight at rt and subjected to aqueous work up. The product may be purified by chromatography or crystallization.

In step 2, the product of step 1 is dissolved in THF, cooled in a dry ice/acetone bath ( $-78^{\circ}\text{C}$ ) and treated with methyllithium, then n-BuLi. The dianion is then treated with a THF solution containing the aldehyde (i). The resulting mixture is warmed to rt and stirred for 10 h. The product is purified by chromatography.

In step 3, the alcohol product from step 2 is dissolved in methylene chloride and treated with ten fold excess of triethylsilane followed by a slight excess of boron trifluoride etherate. The resulting mixture is stirred at room temperature for 4h, and purified by chromatography.

In step 4, the product of step 3 is dissolved in a suitable solvent such as dioxane, ethanol, or THF and an alkali metal hydroxide such as lithium hydroxide is


added either as an aqueous solution or as a solid. The reaction mixture is stirred at rt for 0.5-24 h.

In step 5, the product of step 4 is dissolved in a mixture of a suitable inert solvent such as  $\text{CH}_2\text{Cl}_2$  or dioxane and a tertiary amine base, and a suitable electrophile is added. The reaction mixture is stirred between  $-78^\circ\text{C}$  and  $100^\circ\text{C}$  for 0.5 to 48 h.

In step 6, the product of step 5 is dissolved in a suitable inert solvent such as THF or  $\text{CH}_2\text{Cl}_2$  and treated with a suitable base such as NaH or triethylamine. An electrophile is added and the reaction mixture is stirred between  $0^\circ\text{C}$  and  $100^\circ\text{C}$  for 0.5 to 48 h.

The aldehyde (i) used in step 2 was prepared by one of the following two procedures; 1) Regioselective ortho lithiation of a 4-substituted benzaldehyde, and quenching with a substituted phenyl disulfide followed by oxidation with metachloroperoxybenzoic acid to the sulfone. 2) Base promoted displacement of fluoride from an ortho-fluorobenzaldehyde by a thiophenol, phenol, or aniline.

### General Scheme III Preparation of Ketone and Olefin Linked Compounds




#### Description of reactions-General Scheme III

In step 1 the secondary alcohol, the product of Step 2 in Scheme II is oxidized with PCC, in a suitable inert solvent such as  $\text{CH}_2\text{Cl}_2$ , to the carbonyl by stirring at rt for 18 h. In step 2, the ketone is treated with the ylide obtained by base treatment of dried methyltriphenylphosphonium bromide, providing the exo methylene product. In

step 3 the trifluoroacetamide group can be hydrolyzed with base and reacted with a variety of acylating, sulfonylating, alkylating and other electrophilic reagents.

The ketone product can be treated with hydroxylamine hydrochloride in pyridine and heated at 80°C for 24 h. The mixture was cooled to room temperature and the solvent removed under reduced pressure. Upon workup and purification, the oxime is obtained.

#### General Scheme IV Preparation of Oxygen Linked Compounds



#### Description of reactions-General Scheme IV

In step 1, 2-bromo-4-chlorophenol and a 4-fluorobenzonitrile are dissolved in a polar aprotic solvent such as DMA in the presence of a suitable base such as potassium hydroxide. The reaction mixture is heated for 0.5-7 days. Preferred temperatures are greater than 60 °C. The reaction mixture is diluted with a suitable extraction solvent such as diethyl ether and washed with water. The solvents are removed and the product is purified via sgc.

In step 2, the product of step 1 is dissolved in a solution of diborane in THF. The reaction is stirred at reflux for 1-24 h then quenched with water and partitioned between EtOAc and aq NaOH. The solvents are evaporated and the product is purified by formation of the HCl salt in diethyl ether.

5 In step 3, the product of step 2 is suspended in  $\text{CH}_2\text{Cl}_2$  and a suitable base such as triethylamine is added. The reaction mixture is cooled, and TFAA is added. The reaction mixture is stirred from 0.5 to 8 h, then subjected to aqueous workup. The crude product is purified by sgc.


10 In step 4, the product of step 3 is dissolved in THF and treated with methyl lithium, then n-BuLi at  $-78^\circ\text{C}$  to form a dianion that is trapped with a suitable electrophile. The reaction mixture is quenched with a suitable proton source such as aq  $\text{NH}_4\text{Cl}$  or phosphate buffer then extracted with EtOAc. The product may be purified via sgc or crystallization.

15 In step 5, the product of step 4 is dissolved in a suitable solvent such as dioxane, ethanol, or THF and an alkali metal hydroxide such as lithium hydroxide is added either as an aqueous solution or as a solid. The reaction mixture is stirred at rt for 0.5-24 h.

20 In step 6, the product of step 5 is dissolved in a mixture of a suitable inert solvent such as  $\text{CH}_2\text{Cl}_2$  or dioxane and a tertiary amine base, and a suitable electrophile is added. The reaction mixture is stirred between  $-78^\circ\text{C}$  and  $100^\circ\text{C}$  for 0.5 to 48 h.

In step 7, the product of step 6 is dissolved in a suitable inert solvent such as THF or  $\text{CH}_2\text{Cl}_2$  and treated with a suitable base such as NaH or triethylamine. An electrophile is added and the reaction mixture is stirred between  $0^\circ\text{C}$  and  $100^\circ\text{C}$  for 0.5 to 48 h.

## General Scheme V Preparation of Amide Compounds



### Description of Reactions-General Scheme V

In step 1, 1-chloro-4-fluorobenzene is dissolved in anhyd THF and treated with  
5 n-BuLi at  $-78^\circ\text{C}$  to form an anion that is trapped with a suitable electrophile. The product may be purified via sgc or crystallization.

In step 2, the product of step 1 is dissolved in a suitable polar solvent such as acetonitrile or DMA. A benzoic acid containing a nucleophilic moiety such as an OH, NHR, or SH is added, and two or more equivalents of a suitable base such as  
10 potassium hydroxide or sodium hydride is added. The reaction mixture may be stirred for 1-24 h at temperatures ranging between  $0^\circ\text{C}$  and  $150^\circ\text{C}$ . The reaction mixture is partitioned between water and a suitable solvent such as EtOAc. The product may be purified via sgc or crystallization.


In step 3, the product of step 2 is dissolved in  $\text{CH}_2\text{Cl}_2$ . Pentafluorophenol and  
15 EDCI are added. The reaction mixture is stirred at rt for 0.5-24 h then partitioned between water and  $\text{CH}_2\text{Cl}_2$ . The solvents are evaporated. The product may be purified via sgc or crystallization.

In step 4, the product of step 3 is dissolved in a suitable solvent such as  $\text{CH}_2\text{Cl}_2$ . An amine base such as DIPEA or triethylamine is added, followed by a  
20 primary or secondary amine. The reaction mixture may be stirred for 1-24 h at rt. The reaction mixture is then subjected to aqueous workup and isolation and the product is purified via sgc.



In step 5, if the nucleophilic moiety in step 2 contains oxidizable functionality, the product of step 4 is dissolved in a suitable solvent such as  $\text{CH}_2\text{Cl}_2$  and MCPBA is added. The reaction mixture may be stirred for 0.5-48 h then partitioned between a suitable solvent such as  $\text{CH}_2\text{Cl}_2$  or EtOAc and an aqueous base such as  $\text{Na}_2\text{CO}_3$ . The solvent is evaporated and the product is purified via sgc.

### General Scheme VI C-Ring Addition Elimination Chemistry



#### Description of Reactions-General Scheme VI

In step 1, trifluoroacetic anhydride is dissolved in a suitable inert solvent such as methylene chloride and reacted with a benzyl amine at rt for 1-5 h.

Methanesulfonic acid (2 eq) is added followed by N-iodosuccinamide. The reaction mixture is stirred overnight at rt, then subjected to aqueous work up. The crude product is recrystallized from isopropanol and water.

In step 2, CuCl is dissolved in glacial acetic acid. The flask is cooled to 0 °C and SO<sub>2</sub> gas is bubbled in with stirring for 40 min. In a separate flask 2-fluoro-4-chloroaniline is dissolved in glacial acetic acid and concentrated HCl. The resulting

solution is cooled to 0 °C and treated with an aqueous solution of NaNO<sub>2</sub>. The reaction mixture is stirred for 30 min at 0 °C and the contents are added to the flask containing the SO<sub>2</sub> solution causing vigorous gas evolution. The reaction is then allowed to warm to rt. The product is isolated by pouring the reaction mixture onto  
5 chipped ice, then filtering the resulting solid.

In step 3, the product of step 2 is dissolved in acetone. An aqueous solution of KF (2 eq) is added and the reaction mixture is stirred for 12-24 h at rt. The reaction mixture is extracted with a suitable solvent such as CH<sub>2</sub>Cl<sub>2</sub> or Et<sub>2</sub>O and the solvent is evaporated to afford the product.

10 In step 4, the product of step 1 is dissolved in THF and TMEDA is added. The flask is placed under N<sub>2</sub> blanket, and cooled to 0 °C. A solution of isopropyl magnesium chloride in THF is added and the reaction mixture is stirred for 1-4 h. The resulting solution is added to a flask containing the product of step 3 that was cooled with an ice-water bath. The reaction mixture is stirred for 1-3 h. The reaction is  
15 quenched with aqueous NH<sub>4</sub>Cl and extracted with EtOAc. After evaporation of the solvent, the crude product is purified via sgc.

In step 5, the product of step 4 is dissolved in a suitable solvent such as dioxane, ethanol, or THF and an alkali metal hydroxide such as lithium hydroxide is added either as an aqueous solution or as a solid. The reaction mixture is stirred at rt  
20 for 0.5-24 h. The product may be purified via sgc or crystallization.

In step 6, the product of step 5 is dissolved in a suitable inert solvent such as CH<sub>2</sub>Cl<sub>2</sub> or acetonitrile and a tertiary amine base, and a triflic anhydride is added. The reaction mixture is stirred between -78°C and rt for 0.5 to 48 h. The product may be purified via sgc or crystallization.

25 In step 7, the product of step 6 is dissolved in a suitable inert solvent such as dioxane and a thiol is added. A base such as sodium hydride, sodium hydroxide, or NaHMDS is added and the reaction mixture is stirred at a suitable temperature between 50 °C and 100 °C for 4-24 h. The reaction mixture is quenched with water and extracted with a suitable solvent. The solvents are evaporated and the crude  
30 product is purified via sgc.









In step 8, the product of step 7 is dissolved in a suitable inert solvent such as CH<sub>2</sub>Cl<sub>2</sub>. Na<sub>2</sub>HPO<sub>4</sub> and urea hydrogen peroxide complex is added, followed by TFAA.













The reaction mixture is refluxed for 4-16 h, then partitioned between water and  $\text{CH}_2\text{Cl}_2$ . The solvents are evaporated and the crude product is purified via sgc.















Those skilled in the art will appreciate that similar reactions to those described in the above schemes may be carried out on other compounds of formula I as long as substituents present would not be susceptible to the reaction conditions described.














Starting materials for the above processes are either commercially available, known in the art, or prepared by procedures well known in the art. Exemplary compounds of formula 1 are set forth below in Table I. CB means covalent bond.
















TABLE I

















	$\text{R}^1$	$\text{R}^2$	$\text{R}^3$	$\text{R}^4$	$\text{R}^5$	$\text{R}^6$	$\text{L}^1$	$\text{L}^2$	X	Y	Z
A	$\text{CH}_3$	H	H		H	$\text{CH}_3$	$\text{SO}_2$	$\text{SO}_2$	$\text{OCH}_3$	$\text{SO}_2$	CB
B	$\text{CH}_3$	H	H		H	$\text{CH}_3$	$\text{SO}_2$	$\text{SO}_2$	$\text{OCH}_3$	$\text{SO}_2$	CB
C	$\text{CH}_3$	H	H		H	$\text{CH}_3$	$\text{SO}_2$	$\text{SO}_2$	$\text{OCF}_2\text{H}$	$\text{SO}_2$	CB
D	$\text{CH}_3$	H	H	t-butoxy	H	$\text{CH}_3$	$\text{SO}_2$	CO	$\text{OCH}_3$	$\text{SO}_2$	CB
E	$\text{CH}_3$	H	H		H	$\text{CH}_3$	$\text{CH}_2$	$\text{SO}_2$	$\text{OCF}_3$	$\text{SO}_2$	CB
F	$\text{CH}_3$	H	H		H	$\text{CH}_3$	$\text{SO}_2$	$\text{SO}_2$	$\text{OCH}_3$	$\text{SO}_2$	CB
G	$\text{CH}_3$	H	H		H	$\text{CH}_3$	$\text{SO}_2$	$\text{SO}_2$	$\text{CH}_3$	$\text{SO}_2$	CB
H	$\text{CF}_3$	H	H		H	$\text{CH}_3$	$\text{CH}_2$	$\text{SO}_2$	$\text{CF}_3$	$\text{SO}_2$	CB
I	$\text{CH}_3$	H	H		H	$\text{CH}_3$	$\text{SO}_2$	$\text{SO}_2$	$\text{OCH}_3$	$\text{SO}_2$	CB

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
J	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
K	CH <sub>3</sub>	H	H	t-butoxy	H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	OCF <sub>2</sub> H	SO <sub>2</sub>	CB
L	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
M	CH <sub>3</sub>	H	H		H	H	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
N	CH <sub>3</sub>	H	H		H	H	CH <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
O	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
P	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
Q	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CH <sub>3</sub>	SO <sub>2</sub>	CB
R	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
S	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
T	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
U	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
V	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB



















	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
W	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
X	CF <sub>3</sub>	H	H		CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
Y	C <sub>4</sub> H <sub>9</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
Z	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
AA	CH <sub>3</sub>	H	H	C <sub>3</sub> H <sub>7</sub>	H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
AB	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
AC	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
AE	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
AF	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
AG	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
AH	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
AI	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
AK	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AM	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AO	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
AQ	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AR	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AS	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AT	N(CH <sub>3</sub> ) <sub>2</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AU	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AV	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AW	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AX	CH <sub>3</sub>	H	H	C <sub>3</sub> H <sub>7</sub>	H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
AY	CF <sub>3</sub>	H	H		CH <sub>3</sub>	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	O    C	CB
AZ	CF <sub>3</sub>	H	H		CH <sub>3</sub>	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
BA	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
BB	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
BC	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
BD	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
BG	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
BH	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
BJ	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
BN	CF <sub>3</sub>	H	H	C <sub>3</sub> H <sub>7</sub>	H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
BO	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
BP	NHC <sub>3</sub> H <sub>7</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
BR	CF <sub>3</sub>	H	H		CH <sub>3</sub>	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
BS	CH <sub>3</sub>	H	H		CH <sub>3</sub>	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
BT	CH <sub>3</sub>	CH <sub>3</sub>	H		CH <sub>3</sub>	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
BU	CH <sub>3</sub>	H	H		H	H	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
BV	CH <sub>3</sub>	CH <sub>3</sub>	H		H	H	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
BW	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
BX	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
BY	CH <sub>3</sub>	CH <sub>3</sub>	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
BZ	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CH <sub>3</sub>	SO <sub>2</sub>	CB
CA	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CH <sub>3</sub>	SO <sub>2</sub>	CB

















	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
CB	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CH <sub>3</sub>	SO <sub>2</sub>	CB
CC	CF <sub>3</sub>	H	H	C <sub>3</sub> H <sub>7</sub>	H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	C=O	CB
CD	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
CE	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
CF	-CH(CH <sub>3</sub> ) <sub>2</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
CG	NH <sub>2</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
CH	C <sub>4</sub> H <sub>9</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
CI	-CHCF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
CJ		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
CK		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
CL		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
CM		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
CN	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
































	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
CO		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
CP	C <sub>3</sub> H <sub>7</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
CQ		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
CR		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
CS	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	C=O	CB
CT	NH-(CH <sub>2</sub> ) <sub>2</sub> -CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
CU		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
CV	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	OH	C=O	CB
CW	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OH	SO <sub>2</sub>	CB
CX	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OH	SO <sub>2</sub>	CB
CZ	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCF <sub>2</sub> H	C=O	CB
DA	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCF <sub>2</sub> H	SO <sub>2</sub>	CB
DC	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	OCH <sub>3</sub>	SO <sub>2</sub>	CB
DD	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	OCH <sub>3</sub>	C=O	CB
























Sub  
P
















Chemical structure of the compound is shown in the table. The structure is a substituted benzene ring with a methyl group at the 1-position, a methoxy group at the 4-position, and a chlorine atom at the 2-position. The compound is identified as 2-chloro-4-methoxybenzene.






	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
DE		H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	OCH <sub>3</sub>	C=O	CB
DF	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	Cl	SO <sub>2</sub>	CB
DG	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	Cl	SO <sub>2</sub>	CB
DH	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	CH <sub>2</sub>	Cl	SO <sub>2</sub>	CB
DI	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	Cl	SO <sub>2</sub>	CB
DJ	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	CH <sub>2</sub>	Cl	SO <sub>2</sub>	CB
DK	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	Cl	SO <sub>2</sub>	CB
DL	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=CH <sub>2</sub>	Cl	SO <sub>2</sub>	CB
DM	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>		Cl	C=O	CB
DN	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	Cl	C=O	CB
DP	CF <sub>3</sub>	CH <sub>3</sub>	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=CH <sub>2</sub>	Cl	C=O	CB
DQ	CH <sub>3</sub>	H	H		CH <sub>3</sub>	CH <sub>3</sub>	SO <sub>2</sub>	C=O	Cl	SO <sub>2</sub>	CB
DR	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	NH	Cl	SO <sub>2</sub>	CB
DS	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	O	Cl	C=O	CB

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
DU	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
DV	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
DW	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
DX	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
DY	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
DZ	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
EA	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
EC	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
ED	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	C=O	CB
EE	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
EG	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
EH	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
EI	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
EJ	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
EK	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
EL	CH <sub>3</sub>	H	H		H	H	CH <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
EN	CF <sub>3</sub>	H	H		CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	C=O	CB
EP	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
EU	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
EV	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
EW	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	O	H	C=O	CB
EX	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	O	H	C=O	CB
EY	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	O	Cl	C=O	CB
EZ	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	SO <sub>2</sub>	OCF <sub>3</sub>	C=O	CB
FA	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	NHSO <sub>2</sub>	H	C=O	CB
FB	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	NHCO	H	C=O	CB
FC	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	C=O	CB
FD	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
FE	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=O	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
FF	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	C=NO H	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
FG	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	C(CH <sub>3</sub> ) <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
FH	CF <sub>3</sub>	H	H		H	H	C=O	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB
FI	CH <sub>3</sub>	H	H		H	H	O	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
FJ	*R <sup>1</sup> , Y, Z and R <sup>2</sup> combine to form morpholinyl	*	H		-		S	SO <sub>2</sub>	Cl	*	*
FK	H	CH <sub>3</sub>	H		-		S=O	SO <sub>2</sub>	Cl	CB	CB
FL	H	CH <sub>3</sub>	H		-		SO <sub>2</sub>	SO <sub>2</sub>	Cl	CB	CB
FM	*R <sup>1</sup> , Y, Z and R <sup>2</sup> combine to form morpholinyl	*	H		-		SO <sub>2</sub>	SO <sub>2</sub>	Cl	*	*
FN	CH <sub>3</sub>	CH <sub>3</sub>	H		-		S	SO <sub>2</sub>	Cl	CB	CB
FO	H	H	H		-		S	SO <sub>2</sub>	Cl	CB	CB
FP	CH <sub>3</sub>	CH <sub>3</sub>	H		-		SO <sub>2</sub>	SO <sub>2</sub>	Cl	CB	CB
FQ	H	H	H		-		SO <sub>2</sub>	SO <sub>2</sub>	Cl	CB	CB
FR	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	SO <sub>2</sub>	CB
FS	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	SO <sub>2</sub>	CB
FT	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	SO <sub>2</sub>	CB


	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
FU	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	C=O	CB
FV	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	SO <sub>2</sub>	CB
FW	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	SO <sub>2</sub>	CB
FX	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	C=O	CB
FY	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	SO <sub>2</sub>	CB
FZ	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	H	SO <sub>2</sub>	CB
GA	CH <sub>3</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	C=O	CB
GD		H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
GF	NHC <sub>2</sub> H <sub>5</sub>	H	H		H	CH <sub>3</sub>	CH <sub>2</sub>	SO <sub>2</sub>	OCF <sub>3</sub>	SO <sub>2</sub>	CB
GG	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
GH	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	CF <sub>3</sub>	SO <sub>2</sub>	CB
GI	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	Cl	SO <sub>2</sub>	CB
GJ	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	SO <sub>2</sub>	CB
GK	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	C=O	OCH <sub>3</sub>	SO <sub>2</sub>	CB

	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	L <sup>1</sup>	L <sup>2</sup>	X	Y	Z
GL	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OH	SO <sub>2</sub>	CB
GM	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH(CH <sub>3</sub> ) <sub>2</sub>	SO <sub>2</sub>	CB
GN	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>		SO <sub>2</sub>	CB
GO	CF <sub>3</sub>	H	H		H	CH <sub>3</sub>	SO <sub>2</sub>	SO <sub>2</sub>	OCH <sub>3</sub>	C=O	CB



CB is a covalent bond  
- means that the substituent is not present













5

In a preferred embodiment, there are disclosed compounds of the formula































10 a prodrug thereof, or a pharmaceutically acceptable salt of the compound or of said prodrug; wherein X, R<sup>1</sup> and R<sup>4</sup> are as shown in the table below:

Example	X	R <sup>1</sup>	R <sup>4</sup>
A	OCH <sub>3</sub>	CH <sub>3</sub>	
C	OCF <sub>2</sub> H	CH <sub>3</sub>	


Example	X	R <sup>1</sup>	R <sup>4</sup>
G	CH <sub>3</sub>	CH <sub>3</sub>	
L	Cl	CH <sub>3</sub>	
R	CF <sub>3</sub>	CF <sub>3</sub>	
S	Cl	CF <sub>3</sub>	
AB	CF <sub>3</sub>	CH <sub>3</sub>	
AT	Cl	N(CH <sub>3</sub> ) <sub>2</sub>	
BA	OCF <sub>3</sub>	CH <sub>3</sub>	
BD	OCF <sub>3</sub>	CF <sub>3</sub>	
BZ	CH <sub>3</sub>	CF <sub>3</sub>	
CD	Cl	CH <sub>3</sub>	
FS	H	CH <sub>3</sub>	
FY	H	CF <sub>3</sub>	



Example	X	R <sup>1</sup>	R <sup>4</sup>
GG	Cl	CF <sub>3</sub>	
GH	CF <sub>3</sub>	CF <sub>3</sub>	
XXIX		CF <sub>3</sub>	
XXX		CF <sub>3</sub>	
XXXI		CF <sub>3</sub>	
XXXII	CN	CF <sub>3</sub>	
XXXIII	NH <sub>2</sub>	CF <sub>3</sub>	
XXXIV		CF <sub>3</sub>	
XXXVI	Cl	CF <sub>3</sub>	
XXXVII		CF <sub>3</sub>	
XXXVIII	CN	CF <sub>3</sub>	
XXXIX	-CONH <sub>2</sub>	CF <sub>3</sub>	



















Example	X	R <sup>1</sup>	R <sup>4</sup>
XXXX	-OCH <sub>3</sub>	CF <sub>3</sub>	
XXXXI	-OH	CF <sub>3</sub>	
XXXXII		CF <sub>3</sub>	
XXXXIII		CF <sub>3</sub>	
XXXXIV	H <sub>3</sub> C-CH <sub>2</sub> -O-	CF <sub>3</sub>	
XXXXV	H <sub>3</sub> C-O-CH <sub>2</sub> -CH <sub>2</sub> -O-	CF <sub>3</sub>	
XXXXXV	OCH <sub>3</sub>	CF <sub>3</sub>	
XXXXXVI		CH <sub>3</sub>	

In another preferred embodiment, there are disclosed compounds of the formula



5

a prodrug thereof, or a pharmaceutically acceptable salt of the compound or of said prodrug; wherein X, Y-R<sup>1</sup> and R<sup>4</sup> are as shown in the table below:

Example	X	Y-R <sup>1</sup>	R <sup>4</sup>
XXXXVI			
XXXXVII			
XXXXVIII			
XXXXIX			
XXXXXI	-OCH <sub>3</sub>		
XXXXXII	-OCH <sub>3</sub>		
XXXXXIII	-OCH <sub>3</sub>		

Compound A : <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) 1.54 (d, J = 6.9Hz 3H), 2.67 (s, 3H), 4.72 (q, J = 5Hz 1H), 4.86 (br. d, J = 5Hz, 1H, NH), 7.08-8.42 (m, 11H).

- 5 Compound C : <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 1.51 (d, J = 7.2Hz 3H), 2.67 (s, 3H), 4.702 (q, J = 6.8Hz 1H), 5.05 (br. d, J = 6.4Hz, 1H, NH), 6.71 (t, J = 71.6 Hz, CF<sub>2</sub>H) 7.07-8.47 (m, 11H).

- 10 Compound G : <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) 8.43-8.41 (m, 1H), 8.36 (d, 8Hz, 1H), 8.28-8.22 (m, 1H), 7.96-7.92 (m, 2H), 7.69-7.60 (m, 2H), 7.52-7.47 (m, 2H), 7.43-7.37 (m, 1H), 7.13-7.06 (m, 1H), 4.76-4.70 (m, 2H), 2.68 (s, 3H), 2.59 (s, 3H), 1.41 (d, 7 Hz, 3H).

- 15 Compound L : <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) 8.61-5.97 (m, 2H), 8.40 (d, 8 Hz, 1H), 8.24-8.21 (m, 1H), 7.96 (d, 8 Hz, 2H), 7.86-7.83 (m, 1H), 7.70-7.63 (m, 1H), 7.52 (d, 8

Hz, 2H), 7.46-7.40 (m, 1H), 7.18-7.12 (m, 1H), 4.80-4.70 (m, 1H), 2.71 (s, 3H), 1.56 (d, 7Hz, 3H).

5 Compound R :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.89-8.87 (m, 1H), 8.58 (d, 8Hz, 1H), 8.32-8.25 (m, 1H), 8.15-8.11 (m, 1H), 8.03-7.98 (m, 2H), 7.71-7.63 (m, 1H), 7.52-7.48 (m, 2H), 7.47-7.41 (m, 1H), 7.16-7.09 (m, 1H), 5.62 (d, 8 Hz, 1H), 4.90-4.80 (m, 1H), 1.63 (d, 7 Hz, 3H).

10 Compound S :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.61-8.59 (m, 1H), 8.39 (d, 8 Hz, 1H), 8.29-8.24 (m, 1H), 7.99 (d, 8 Hz, 2H), 7.86-7.82 (m, 1H), 7.67-7.62 (m, 1H), 7.49 (d, 8Hz, 1H), 7.46-7.40 (m, 1H), 7.16-7.10 (m, 1H), 4.89-4.84 (m, 1H), 1.65 (d, 6 Hz, 1H).

15 Compound AB :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.88-8.86 (m, 1H), 8.62-8.59 (m, 1H), 8.30-8.29 (m, 1H), 8.15-8.11 (m, 1H), 8.00-7.96 (m, 2H), 7.71-7.63 (m, 1H), 7.56-7.52 (m, 2H), 7.47-7.41 (m, 1H), 7.16-7.09 (m, 1H), 4.99-4.84 (m, 1H), 4.80-4.70 (m, 1H), 2.71 (s, 3H), 1.54 (d, 7Hz, 3H).

20 Compound AT :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.51 (br s 1H), 8.39 (d, 8 Hz, 2H), 7.99 (d, 8 Hz, 2H), 7.86-7.83 (m, 1H), 7.61-7.50 (m, 1H), 7.49 (d, 8 Hz), 7.05-6.99 (m, 1H), 4.70-4.50 (m, 2H), 2.83 (s, 3H), 2.57 (s, 3H), 1.50 (d, 7 Hz, 3H).

Compound BA :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 1.54 (d,  $J = 6.9$  Hz 3H), 2.7 (s, 3H), 4.72 (q,  $J = 5.5$ Hz 1H), 5.05 (br. d,  $J = 5$ Hz, 1H, NH), 7.1 -8.55 (m, 11H).

25 Compound BD :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.51 (d, 9 Hz, 1H), 8.47-8.45 (m, 1H), 8.01-7.97 (m, 2H), 7.71-7.63 (m, 2H), 7.52-7.41 (m, 3H), 7.17-7.10 (m, 1H), 5.51 (d, 8 Hz, 1H), 4.90-4.80 (m, 1H), 1.64 (d, 7 Hz, 3H).

30 Compound BZ :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.43 (br s, 1H), 8.32 (d, 8 Hz, 1H), 8.28-8.22 (m, 1H), 7.94 (d, 8 Hz, 2H), 7.68-7.58 (m, 2H), 7.47-7.37 (m, 3H), 7.12-7.06 (m, 1H), 5.72 (d, 8 Hz, 1H), 4.86-4.70 (m, 1H), 2.59 (s, 3H), 1.60 (d, 7 Hz, 3H).

35 Compound CD :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ): 8.82-8.78 (m, 1H), 8.23 (d, 7 Hz, 2H), 8.21-8.07 (m, 1H), 7.81-7.77 (m, 2H), 7.63-7.57 (m, 1H), 7.55 (d, 7 Hz, 2H), 7.40-7.32 (m, 1H), 7.20-7.16 (m, 1H), 4.8-4.7 (m, 2H), 2.67 (s, 3H), 1.55 (d, 7 Hz, 2H).

40 Compound FS :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.66-8.62 (m, 1H), 8.51-8.47 (m, 1H), 8.29-8.24 (m, 1H), 7.99-7.95 (m, 2H), 7.93-7.89 (m, 2H), 7.67-7.53 (m, 1H), 7.50-7.44 (m, 2H), 7.42-7.39 (m, 1H), 7.13-7.07 (m, 1H), 4.78-4.73 (m, 1H), 4.61-4.59 (m, 1H), 2.70 (s, 3H), 1.56 (d, 7 Hz, 3H).

45 Compound FY :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.66-8.63 (m, 1H), 8.49-8.46 (m, 1H), 8.28-8.25 (m, 1H), 8.01 (d, 8 Hz, 2H), 7.93-7.89 (m, 2H), 7.65-7.58 (m, 1H), 7.56 (d, 8 Hz, 2H), 7.47-7.41 (m, 1H), 7.13-7.07 (m, 1H), 5.18 (d, 6 Hz, 1H), 4.90-4.80 (m, 1H), 1.66 (d, 7 Hz, 3H).

Compound GG :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ): 8.88 (d, 1.2 Hz, 1H), 8.51-8.56 (m, 2H), 8.31 (dd, 8 Hz, 1H, 1H), 8.18 (dd, 8 Hz, 1 Hz, 1H), 8.08-7.96 (m, 3H), 7.62-7.48 (m, 3H), 5.51 (d, 9 Hz, 1H), 4.90-4.70 (m, 1H), 1.62 (d, 7 Hz, 3H).

- 5 Compound GH :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ): 8.63 (d, 2 Hz), 8.58-8.55 (m, 1H), 8.34-8.28 (m, 2H), 8.07-7.98 (m, 3H), 8.35 (dd, 8 Hz, 2 Hz, 1H), 7.55-7.46 (m, 3H), 5.34 (d, 8 Hz, 1H), 4.9-4.8 (m, 1H), 1.64 (d, 6 Hz, 3H).
- 10 Compound GQ/XXIX, :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.56-8.52 (m, 1H), 8.32-8.21 (m, 3H), 8.02-7.92 (m, 4H), 5.42 (d, 9 Hz, 1H), 8.02-7.92 (m, 4H), 5.42 (d, 1H, 9 Hz), 4.84-4.78 (m, 1H), 2.16-2.06 (m, 1H), 1.60 (d, 7Hz, 3H), 1.20-1.17 (m, 2H), 0.97-0.89 (m, 1H).
- 15 Compound GR/XXX, :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.33-8.22 (m, 3H), 8.00-7.94 (m, 2H), 7.66-7.58 (m, 1H), 7.53-7.37 (m, 4H), 7.16-7.05 (m, 1H), 5.160 (d, 9 Hz, 1H), 4.88-4.83 (m, 1H), 2.17-2.06 (m, 1H), 1.65 (d, 7 Hz, 3H), 1.28-1.20 (m, 2H), 0.97-0.90 (m, 2H).
- 20 Compound GS/XXXI, :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.38-8.29 (m, 2H), 8.17 (d, 8 Hz, 1H), 8.07-8.02 (m, 1H), 7.91-7.85 (m, 2H), 7.56-7.36 (m, 5H), 6.11 (d, 8 Hz, 1H), 4.84-4.78 (m, 1H), 2.12-2.01 (m, 1H), 1.57 (d, 7Hz, 3H), 1.21-1.12 (m, 2H), 0.92-0.86 (m, 2H).
- 25 Compound GW/XXXVI, :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  10.19 (d, 7.8 Hz, 1H), 8.27-8.42 (m, 4H), 8.13 (dd, 7.8 Hz, 2.1 Hz, 1H), 7.93 (d, 8.4 Hz, 2H), 7.78-7.63 (m, 2H), 7.59 (d, 8.4 Hz, 2H), 4.80 (m, 1H), 1.44 (d, 6.9 Hz, 3H).
- 30 Compound HO/XXXXXXV, :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.56 (d, 3.9 Hz, 1H), 8.31-8.22 (m, 2H), 8.124 (d, 2.7 Hz, 1H), 8.05-7.95 (m, 1H), 7.92 (d, 8.4 Hz, 2H), 7.50-7.45 (m, 1H), 7.92 (d, 8.4 Hz, 2H), 7.27-7.23 (m, 2H), 5.8 (d, NH, 1H), 4.85-4.75 (m, 1H), 3.99 (s, 3H), 1.58 (d, 7.2 Hz, 3H).
- 35 Compound HP/XXXXXXVI, :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.56-8.52 (m, 1H), 8.31-8.23 (m, 3H), 8.02-7.90 (M, 4H), 4.87-4.78 (d, 7 Hz, 1H), 4.69 (m, 1 H), 2.66 (s, 3H), 2.16-2.06 (m, 1H), 1.51 (d, 7 Hz, 3H), 1.27 -1.17 (m, 2H), 0.96-0.90 (m, 2H).

The compounds of the present invention exhibit anti-inflammatory and/or immunomodulatory activity and are useful in the treatment of various medical

- 40 conditions including, e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, osteoporosis, renal ischemia, cerebral stroke, cerebral ischemia, nephritis, psoriasis, allergy, inflammatory disorders of the lungs and gastrointestinal tract such as Crohn's disease, and respiratory tract disorders such as reversible airway obstruction, asthma, chronic obstructive pulmonary disease (COPD)

and bronchitis. This utility is manifested as demonstrated by activity in the following assay.

Potential cannabinoid receptor ligands were screened for the ability to compete with [<sup>3</sup>H] CP-55,940 for binding to recombinant cannabinoid receptors. Test

5 compounds were serially diluted in Diluent Buffer (50 mM Tris pH 7.1, 1 mM EDTA, 3 mM MgCl<sub>2</sub>, 0.1% BSA, 10% DMSO, 0.36% methyl cellulose (Sigma M-6385)) from stocks prepared in 100% DMSO. Aliquots (10 ul) were transferred into 96-well microtiter plates. Membrane preparations of recombinant human cannabinoid CB2 receptor (Receptor Biology #RB-HCB2) or recombinant human cannabinoid CB1  
10 receptor (Receptor Biology #RB-HCB1) were diluted to 0.3 mg/ml in Binding Buffer (50 mM Tris pH 7.2, 1 mM EDTA, 3 mM MgCl<sub>2</sub>, 0.1% BSA). Aliquots (50 ul) were added to each well of the microtiter plate. The binding reactions were initiated by addition of [<sup>3</sup>H] CP-55,940 (New England Nuclear # NET 1051; specific activity =180 Ci/mmol) to each well of the microtiter plate. Each 100 ul reaction mixture contained  
15 0.48 nM [<sup>3</sup>H] CP-55,940, 15 ug membrane protein in binding buffer containing 1% DMSO and 0.036 % methyl cellulose. Following incubation for 2 hours at room temperature, the reactions were filtered through 0.5% polyethylenimine-coated GF/C filter plates (UniFilter-96, Packard) with a TomTec Mark 3U Harvester (Hamden, CT). The filter plate was washed 5 times with binding buffer, rotated 180°, then re-washed  
20 5 times with binding buffer. Bound radioactivity was quantitated following addition of 30 ul of Packard Microscint 20 scintillant in a Packard TopCount NXT microplate scintillation counter. Non-linear regression analysis of the resulting data was performed using Prism 2.0b (GraphPad, San Diego, CA).

Cannabinoid receptor ligands according to the present invention have anti-  
25 inflammatory activity and/or immunomodulatory activity and are useful in the treatment of various medical conditions including, e.g., cutaneous T cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing aveolitis,  
30 psoriasis, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn's disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD) or

bronchitis. It is contemplated that a compound of this invention may be useful in treating more than one of the diseases listed.

Additionally, a compound of the present invention may be co-administered or used in combination with disease-modifying antirheumatic drugs (DMARDS) such as methotrexate, azathioprine, leflunomide, pencillinamine, gold salts, mycophenolate mofetil, cyclophosphamide and other similar drugs. They may also be co-administered with or used in combination with NSAIDS such as piroxicam, naproxen, indomethacin, ibuprofen and the like; COX-2 selective inhibitors such as Vioxx® and Celebrex®; COX-1 inhibitors such as Feldene; immunosuppressives such as steroids, cyclosporine, Tacrolimus, rapamycin and the like; biological response modifiers (BRMs) such as Enbrel, Remicade, IL-1 antagonists, anti-CD40, anti-CD28, IL-10, anti-adhesion molecules and the like; and other anti-inflammatory agents such as p38 kinase inhibitors, PDE4 inhibitors, TACE inhibitors, chemokine receptor antagonists, Thalidomide and other small molecule inhibitors of pro-inflammatory cytokine production. Other drugs that the compounds of the invention may be co-administered or used in combination with include Anaprox, Arava, Arthrotec, Azulfidine, Aspirin, Cataflam, Celestone Soluspan, Clinoril, Cortone Acetate, Cuprimine, Daypro, Decadron, Depen, Depo-Medrol, Disalcid, Dolobid, Naprosyn, Gengraf, Hydrocortone, Imuran, Indocin, Lodine, Motrin, Myochrysine, Nalfon, Naprelan, Neoral, Orudis, Oruvail, Pediapred, Plaquenil, Prelone, Relafen, Solu-Medrol, Tolectin, Trilisate and Volataren. These include any formulation of the abovenamed drugs.

For the treatment of multiple sclerosis, the compounds of the invention may be co-administered or used in combination with Avonex, Betaseron and Copaxone.

For combination treatment with more than one active agent, where the active agents are in separate dosage formulations, the active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of the other agent.

The present invention also relates to a pharmaceutical composition comprising a compound of formula I of this invention and a pharmaceutically acceptable carrier. The compounds of formula I can be administered in any conventional dosage form known to those skilled in the art. Pharmaceutical compositions containing the compounds of formula I can be prepared using conventional pharmaceutically acceptable excipients and additives and conventional techniques. Such

pharmaceutically acceptable excipients and additives include non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavorings, thickeners, coloring agents, emulsifiers and the like. All routes of administration are contemplated including, but not limited to, parenteral, transdermal, subcutaneous, intramuscular, sublingual, inhalation, rectal and topical.

Thus, appropriate unit forms of administration include oral forms such as tablets, capsules, powders, cachets, granules and solutions or suspensions, sublingual and buccal forms of administration, aerosols, implants, subcutaneous, intramuscular, intravenous, intranasal, intraocular or rectal forms of administration.

When a solid composition is prepared in the form of tablets, e.g., a wetting agent such as sodium lauryl sulfate can be added to micronized or non-micronized compounds of formula I and mixed with a pharmaceutical vehicle such as silica, gelatin starch, lactose, magnesium stearate, talc, gum arabic or the like. The tablets can be coated with sucrose, various polymers, or other appropriate substances. Tablets can be treated so as to have a prolonged or delayed activity and so as to release a predetermined amount of active principle continuously or at predetermined intervals, e.g., by using ionic resins and the like.

A preparation in the form of gelatin capsules may be obtained, e.g., by mixing the active principle with a diluent, such as a glycol or a glycerol ester, and incorporating the resulting mixture into soft or hard gelatin capsules.

A preparation in the form of a syrup or elixir can contain the active principle together, e.g., with a sweetener, methylparaben and propylparaben as antiseptics, flavoring agents and an appropriate color.

Water-dispersible powders or granules can contain the active principle mixed, e.g., with dispersants, wetting agents or suspending agents, such as polyvinylpyrrolidone, as well as with sweeteners and/or other flavoring agents.

Rectal administration may be provided by using suppositories which may be prepared, e.g., with binders melting at the rectal temperature, for example cocoa butter or polyethylene glycols.

Parenteral, intranasal or intraocular administration may be provided by using, e.g., aqueous suspensions, isotonic saline solutions or sterile and injectable solutions containing pharmacologically compatible dispersants and/or solubilizers, for example, propylene glycol or polyethylene glycol.



Thus, to prepare an aqueous solution for intravenous injection, it is possible to use a co-solvent, e.g., an alcohol such as ethanol or a glycol such as polyethylene glycol or propylene glycol, and a hydrophilic surfactant such as Tween® 80. An oily solution injectable intramuscularly can be prepared, e.g., by solubilizing the active principle with a triglyceride or a glycerol ester.

Topical administration can be provided by using, e.g., creams, ointments or gels.

Transdermal administration can be provided by using patches in the form of a multilaminate, or with a reservoir, containing the active principle and an appropriate solvent.


Administration by inhalation can be provided by using, e.g., an aerosol containing sorbitan trioleate or oleic acid, for example, together with trichlorofluoromethane, dichlorofluoromethane, dichlorotetrafluoroethane or any other biologically compatible propellant gas; it is also possible to use a system containing the active principle, by itself or associated with an excipient, in powder form.

The active principle can also be formulated as microcapsules or microspheres, e.g., liposomes, optionally with one or more carriers or additives.

Implants are among the prolonged release forms which can be used in the case of chronic treatments. They can be prepared in the form of an oily suspension or in the form of a suspension of microspheres in an isotonic medium.


The daily dose of a compound of formula I for treatment of a disease or condition cited above is about 0.001 to about 100 mg/kg of body weight per day, preferably about 0.001 to about 10 mg/kg. For an average body weight of 70 kg, the dosage level is therefore from about 0.1 to about 700 mg of drug per day, given in a single dose or 2-4 divided doses. The exact dose, however, is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

EXAMPLE I




Compound 1

**Compound 1.** TFAA (67 mL, 0.474 mol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (300 mL) and cooled in an ice water bath. A solution of (S)- $\alpha$ -methylbenzylamine (56.4 g, 0.465 mol) dissolved in  $\text{CH}_2\text{Cl}_2$  (100 mL) was added and the ice bath was removed. The reaction mixture was stirred at rt for 3 h. The reaction mixture was cooled in an ice bath and MsOH (80 mL, 1.23 mol) was added followed by DBDMH (65 g, 0.227 mol). The reaction mixture was left stirring overnight at rt then quenched with 1M aq  $\text{NaHSO}_3$ . The organic layer was washed with water and brine, dried with  $\text{MgSO}_4$ , and concentrated to give 130 g of white solid. The crude product was recrystallized from  $\text{Et}_2\text{O}$  and hexanes giving 46 g (32%) of intermediate Compound 1 as a solid.



Compound 2


**Compound 2.** In a flame dried flask under  $\text{N}_2$  blanket, Compound 1 (12.35 g, 41.2 mmol) was dissolved in dry THF (165 mL) and cooled to  $-78^\circ\text{C}$ . Methyllithium (1.4 M in  $\text{Et}_2\text{O}$ , 30 mL, 42 mmol) was added and the reaction mixture was stirred for 5 min.  $n\text{-BuLi}$  (1.6 M in hexanes, 26 mL, 42 mmol) was added followed after 10 min by  $p$ -methoxybenzenesulfonyl fluoride (8.64 g, 45.4 mmol) which was prepared by standard methods. The cold bath was removed after 10 min and the reaction mixture was allowed to warm to rt over 45 min then quenched with pH 7 sodium phosphate buffer (1 M, 100 mL, 100 mmol). The reaction mixture was extracted with  $\text{EtOAc}$  and the resulting organic layer was washed with brine and dried with  $\text{MgSO}_4$ . After evaporation of the solvent, the crude product was purified by sgc (20%-50%  $\text{EtOAc}$ /hexanes gradient) to give 10.39 g (65%) of Compound 2 as a solid.



5

Compound 3


**Compound 3.** In a flame dried flask under N<sub>2</sub> blanket, Compound 2 (11.09 g, 28.6 mmol) was dissolved in anhyd THF (100 mL) and cooled to -78°C. A solution of n-BuLi (2.5 M in hexanes, 24 mL, 60 mmol) was added and the reaction mixture was stirred for 40 min. Bis-4-methoxyphenyl disulfide (8.76 g / 31.5 mmol) was added and the reaction mixture was stirred at -78 °C for 40 min then between -15 °C and -30 °C for 5 h then quenched with pH 7.0 sodium phosphate buffer (1.0 M, 120 mL). The reaction mixture was partitioned between EtOAc and water. The aqueous layer was extracted with additional EtOAc. The combined organic layer was washed with aq Na<sub>2</sub>CO<sub>3</sub> and brine, then dried with MgSO<sub>4</sub> and concentrated to dryness. The crude product (13.8 g yellow foam) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (120 mL) and cooled to 0°C. MCPBA (18.5 g, ca 107 mmol) was added, followed by additional CH<sub>2</sub>Cl<sub>2</sub> (40 mL). The ice bath was removed and the reaction mixture was stirred at rt for overnight. Aqueous NaHCO<sub>3</sub> (200 mL) and CH<sub>2</sub>Cl<sub>2</sub> were added and the layers were separated. The organic layer was washed with aq NaHSO<sub>3</sub>, NaHCO<sub>3</sub>, H<sub>2</sub>O, and brine then dried with MgSO<sub>4</sub>. The crude product was purified by sgc (30% to 50% EtOAc/hexanes gradient) to give 7.21 g (45%) of Compound 3.



25


Compound 4

**Compound 4.** Compound 3 (4.47 g, 8.02 mmol) was dissolved in p-dioxane (16 mL) and cooled to 0 °C. LiOH (1.0 M aq, 10 mL, 10 mmol) was added and the ice bath was removed. The reaction mixture was stirred at rt for 6 h then concentrated. CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and NaOH (1.0 M aq, 10 mL) were added and the layers were separated. The aqueous layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> and the combined organic layer was dried with MgSO<sub>4</sub> and concentrated. The crude product was purified by sgc (2%-10% MeOH (NH<sub>3</sub>)/CH<sub>2</sub>Cl<sub>2</sub> gradient mobile phase) to give 3.23 g (87%) of Compound 4.




Compound I

**Compound I.** Compound 4 (3.08 g, 6.67 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (33 mL) and triethylamine (1.40 mL, 10.0 mmol) then cooled to 0 °C. MsCl (569 µL, 7.34 mmol) was added and the reaction mixture was stirred at 0 °C for 1 h and 15 min. Citric acid (0.5 M, 40 mL) and additional CH<sub>2</sub>Cl<sub>2</sub> were added and the layers were separated. The organic layer was washed with citric acid, NaHCO<sub>3</sub>, and brine then dried with MgSO<sub>4</sub>. The solvent was evaporated and the crude product was purified by sgc (40%-70% EtOAc/hexanes gradient) to give 3.44 g (96%) of Compound I as a solid.



Compound II


**Compound II.** Compound 4 (27.5 mg, 0.0595 mmol) was dissolved in methylene chloride (226  $\mu$ L) and DIPEA (12  $\mu$ L). A solution of propionyl chloride dissolved in 1,2-dichloroethane (1 M, 75  $\mu$ L, 0.075 mmol) was added and the reaction mixture was shaken at room temperature overnight. Tris(2-aminoethyl)amine polystyrene (4.1 mmol N/g, ca 60 mg) was added to the reaction mixture. The reaction mixture was shaken for an additional hour at rt. The crude product was concentrated, then dissolved in EtOAc and filtered through a silica-gel SepPak (Waters Corp.). The resulting filtrate was concentrated to give 9 mg (29%) of Compound II.



Compound III

**Compound III.** Compound 4 (25 mg, 0.054 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (270  $\mu$ L). A solution of phenyl isocyanate dissolved in toluene (1.0 M, 65 mL, 0.065 mmol) was added and the reaction mixture was shaken at rt overnight. Tris(2-aminoethyl) amine polystyrene (4.1 mmol N/g, ca 60 mg) was added to the reaction mixture and the reaction mixture was shaken for an additional 40 min at rt. EtOAc was added and the reaction mixture was filtered through a silica gel SepPak (Waters Corp.). The resulting filtrate was concentrated to give 18 mg (57%) of Compound III.


#### EXAMPLE II



Compound 5

**Compound 5.** In a 3-necked flame-dried flask under N<sub>2</sub> blanket Compound 1 (40.0 g, 134 mmol) was dissolved in anhyd THF (535 mL) and cooled to -75 °C


(internal temperature). A solution of methyllithium (1.4 M in diethyl ether, 105 mL, 147 mmol) was added at a rate that kept the internal temperature below -60 °C. The reaction was stirred for 15 min and a solution of n-BuLi (2.5 M in hexanes, 62 mL, 155 mmol) was added at a rate that maintained the internal temperature of the reaction below -65 °C. The reaction mixture was stirred for 40 min. and a solution of bis(4-chlorophenyl) disulfide (42 g, 146 mmol) dissolved in anhyd THF (90 mL) was added via addition funnel over 1 h. The reaction mixture was stirred for 3 h then quenched with HCl (1 M aqueous, 200 mL, 200 mmol). EtOAc (500 mL) was added and the layers were separated. The aqueous layer was extracted with 500 mL EtOAc, and the combined organic layer was washed with 1 M aq KOH, water, and brine. After drying with MgSO<sub>4</sub>, the solvent was evaporated to give 54.1 g of a solid. The crude product (52.3 g) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (750 mL) and cooled to 2 °C (internal temp). MCPBA (60%, 184 g) was added in portions over 1 hr and 20 min keeping the internal temperature below 15 °C. The reaction mixture was stirred an additional 2 h. NaOH (1 M aq, 500 mL) and CH<sub>2</sub>Cl<sub>2</sub> were added and the layers were separated. The aqueous layer was extracted with an additional 300 mL of CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was washed with 1M aqueous NaOH, water, and brine, then dried with MgSO<sub>4</sub>. After evaporation of the solvent, a solid (65 g) was obtained. The crude product was partially purified by trituration from Et<sub>2</sub>O/hexanes to give 33.3 g of a solid which was subsequently purified via sgc (20%-25% EtOAc/hexanes) to give 30 g (57%) of Compound 5 as a solid.



Compound 6


**Compound 6.** In a flame dried 3-necked flask under N<sub>2</sub> blanket Compound 5 (44 g, 112 mmol) was dissolved in anhyd THF (450 mL) and cooled in a dry ice/IPA bath. A solution of n-butyl lithium (2.5 M in hexanes, 92 mL, 230 mmol) was added at a rate that maintained the internal reaction temperature below -60 °C, and the reaction mixture was stirred for 1 h. A solution of 2-fluorobenzenesulfonyl fluoride (22.3 g, 125 mmol) dissolved in anhyd THF (20 mL) was added and the reaction

mixture was left stirring overnight and allowed to warm to rt. The reaction mixture was cooled to 0 °C and quenched with saturated aq ammonium chloride (300 mL). EtOAc (600 mL) and brine (25 mL) were added and the layers were separated. The organic layer was washed with water and brine, then dried with MgSO<sub>4</sub>. The solvents were  
5 evaporated giving a foam (62 g). The product was purified by sgc (20%-25% EtOAc/hexanes mobile phase) giving 9.1 g (15%) of Compound 6.



Compound 7

**Compound 7.** Compound 6 (6.77 g, 12.3 mmol) was dissolved in dioxane (15 mL) and cooled in an ice bath. Aqueous lithium hydroxide (1 M, 15 mL, 15 mmol) was added and the reaction mixture was left stirring overnight. The reaction mixture was  
15 concentrated, then partitioned between CH<sub>2</sub>Cl<sub>2</sub> and water. The aqueous layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> and the combined organic layer was dried with MgSO<sub>4</sub>. Evaporation of the solvent afforded 5.66 g of a foam which was purified by sgc (10% MeOH (NH<sub>3</sub>)/CH<sub>2</sub>Cl<sub>2</sub>) to give 4.27 g of Compound 7 (77%).




Compound IV

**Compound IV.** Compound 7 (2.66 g, 5.86 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (28  
25 mL) and triethylamine (0.98 mL) and cooled to 0°C. MsCl (0.499 mL, 6.45 mmol) was added and the reaction mixture was stirred at 0 °C for 6 h. The reaction mixture was partitioned between water and CH<sub>2</sub>Cl<sub>2</sub>. The aqueous layer was extracted with

additional  $\text{CH}_2\text{Cl}_2$  and the combined organic layer was dried with  $\text{MgSO}_4$ . Evaporation of the solvent afforded 3.0 g of a foam which was purified by sgc (40%-50% EtOAc/hexanes gradient) to give 2.77 g (89%) of Compound IV.

- 5 Compound IV :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.61-5.97 (m, 2H), 8.40 (d, 8 Hz, 1H), 8.24-8.21 (m, 1H), 7.96 (d, 8 Hz, 2H), 7.86-7.83 (m, 1H), 7.70-7.63 (m, 1H), 7.52 (d, 8 Hz, 2H), 7.46-7.40 (m, 1H), 7.18-7.12 (m, 1H), 4.80-4.70 (m, 1H), 2.71 (s, 3H), 1.56 (d, 7Hz, 3H).




Compound V

- 10 **Compound V.** Compound 7 (26.1 g, 57.4 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (200mL) and triethylamine (20 mL) and cooled to  $-78^\circ\text{C}$ . Triflic anhydride (10.45 mL, 62.1 mmol) was added and the reaction mixture was stirred for 3 h. The reaction was quenched with water and the layers were separated. The organic layer was washed with water and brine, then dried with  $\text{MgSO}_4$ . The solvent was evaporated to give 42 g of a foam. The crude product was purified *via* sgc (33%-50% EtOAc/hexanes gradient) to give 29.7 g (88%) of Compound V.

25 Compound V :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.61-8.59 (m, 1H), 8.39 (d, 8 Hz, 1H), 8.29-8.24 (m, 1H), 7.99 (d, 8 Hz, 2H), 7.86-7.82 (m, 1H), 7.67-7.62 (m, 1H), 7.49 (d, 8Hz, 1H), 7.46-7.40 (m, 1H), 7.16-7.10 (m, 1H), 4.89-4.84 (m, 1H), 1.65 (d, 6 Hz, 1H).






Compound VI

- 5        **Compound VI.** Compound V (300 mg, 0.512 mmol) was dissolved in methanol (60 mL). Sodium bicarbonate (720 mg, 8.57 mmol) and 5% palladium on carbon (480 mg) were added. The reaction mixture was shaken on a Parr apparatus under 52 psi of hydrogen gas overnight. The reaction mixture was filtered and the solvent was evaporated. The resulting material was partitioned between EtOAc and aq NaHCO<sub>3</sub>.
- 10      The organic layer was dried with MgSO<sub>4</sub> and the solvents were evaporated. The crude product was purified *via* sgc (33% EtOAc/hexanes) to give 257 mg (91%) of Compound VI.

EXAMPLE III


15



Compound 8

- 20        **Compound 8.** In a flame dried 3-necked flask under N<sub>2</sub> blanket Compound 5 (35.7 g, 91 mmol) was dissolved in anhyd THF (360 mL) and cooled in a dry ice/IPA bath. A solution of n-BuLi (2.5 M in hexanes, 76 mL, 190 mmol) was added at a rate that maintained the internal temperature below -60 °C. The reaction mixture was stirred for 1 h. A solution of 2,6-difluorobenzenesulfonyl fluoride (19.47 g, 99.28 mmol) dissolved in anhyd THF (60 mL) was added. The reaction mixture was stirred
- 25      for 2.5 h, then quenched with saturated aq NH<sub>4</sub>Cl (400 mL). EtOAc (500 mL) was added and the layers were separated. The aq layer was extracted with EtOAc and the


combined organic layer was washed with brine and dried with  $\text{MgSO}_4$ . The solvent was evaporated to give 60.7 g of an oil which was purified by sgc (15%-40% EtOAc/hexanes gradient) giving 14.4 g (28%) of Compound 8.



5

Compound 9

**Compound 9.** Compound 8 (21.1 g, 37.2 mmol) was dissolved in dioxane (47 mL) and aq lithium hydroxide (1.0 M, 41 mL, 41 mmol) was added. After 5.5 h, additional LiOH (20 mL) was added and the reaction mixture was stirred overnight. The reaction mixture was extracted with  $\text{CH}_2\text{Cl}_2$ , and partitioned between  $\text{CH}_2\text{Cl}_2$  and water. The aq layer was extracted with additional  $\text{CH}_2\text{Cl}_2$  and the combined organic layer was dried with  $\text{MgSO}_4$ . The solvents were evaporated to give 17.6 g of a foam and the crude product was purified by sgc (1%-3% MeOH ( $\text{NH}_3$ )/ $\text{CH}_2\text{Cl}_2$  gradient) to give 12.2 g (69%) of Compound 9.



20

Compound VII

**Compound VII.** Compound 9 (10.7 g, 22.6 mmol) was dissolved in a mixture of  $\text{CH}_2\text{Cl}_2$  (90 mL) and triethylamine (8 mL) and cooled to  $-78^\circ\text{C}$ . Triflic anhydride (3.80 mL, 22.6 mmol) was added and the reaction mixture was stirred for 2 h. The reaction was quenched with saturated aq  $\text{NaHCO}_3$  and the layers were separated. The aqueous layer was extracted with  $\text{CH}_2\text{Cl}_2$ . The combined organic layer was


25

washed with brine and dried with  $\text{MgSO}_4$ . The solvents were evaporated and the crude product was purified by sgc to give 9.88 g (73%) of Compound VII.

#### EXAMPLE IV

5

**Compound 5.** In a flame dried flask under  $\text{N}_2$  blanket Compound 1 (39.2 g, 132 mmol) was dissolved in anhyd THF (1 L) and cooled in a dry ice/acetone bath. A solution of methyllithium (1.6 M in  $\text{Et}_2\text{O}$ , 82.7 mL, 132 mmol) was added followed by a solution of *n*-BuLi (2.5 M in hexanes, 53 mL, 133 mmol). The reaction mixture was stirred for 25 min and a solution of bis(4-trifluoromethylphenyl) disulfide (46.9 g, 132 mmol) dissolved in THF (200 mL) was added. The reaction mixture was stirred for 2 h then allowed to warm to rt overnight. The reaction was quenched with water and concentrated. The resulting mixture was diluted with EtOAc, washed with water, and dried with  $\text{Na}_2\text{SO}_4$ . The solvent was evaporated and the crude product was purified via sgc (20% EtOAc/hexanes) to give 49.2 g (95%) of a solid. This material (49.2 g) was dissolved in  $\text{CH}_2\text{Cl}_2$  (1.2 L) and cooled in an ice bath. MCPBA (60%, 90 g) was added in small portions. After 1 h, the ice bath was removed and the reaction mixture was stirred overnight at rt. The reaction mixture was partitioned between  $\text{CH}_2\text{Cl}_2$  and 10% aqueous  $\text{NaHCO}_3$ . The combined organic layer was washed with water and dried with  $\text{Na}_2\text{SO}_4$ . The solvent was evaporated and the crude product was purified by sgc (25% EtOAc/hexanes) to give 46.3 g (85%) of Compound 5.




25

Compound 10

**Compound 10.** In a flame dried flask under  $\text{N}_2$  blanket, Compound 5 (21.55 g, 50.7 mmol) was dissolved in anhyd THF (300 mL) and cooled in a dry ice/IPA bath. A solution of methyllithium (1.6 M in  $\text{Et}_2\text{O}$ , 32 mL, 51 mmol) was added, followed by *n*-BuLi (2.5 M in hexanes, 20.3 mL, 50.7 mmol) and the reaction mixture was stirred for


30

10 min. A solution of bis-(2-fluorophenyl) disulfide (14.2 g, 55.7 mmol) dissolved in THF was added and the reaction mixture was stirred for 2 h at  $-78^{\circ}\text{C}$ . The ice bath was removed and the reaction mixture was allowed to warm to rt and left stirring overnight. The reaction mixture was quenched with saturated aqueous  $\text{NH}_4\text{Cl}$  and extracted with EtOAc. The organic layer was dried with  $\text{Na}_2\text{SO}_4$  and the solvents were evaporated. The crude product was purified via sgc (25% EtOAc/hexanes) to give 23.2 g of a solid. This material was dissolved in  $\text{CH}_2\text{Cl}_2$  (400 mL) and cooled in an ice bath. MCPBA (60%, 30.3 g) was added in several portions and the reaction mixture was stirred for 1 h. The ice bath was removed and the reaction mixture was left stirring overnight. The reaction mixture was partitioned between  $\text{CH}_2\text{Cl}_2$  and 5% aq  $\text{Na}_2\text{CO}_3$ . The organic layer was washed with water and dried with  $\text{Na}_2\text{SO}_4$ . The solvents were evaporated and the crude product was purified *via* sgc (25%EtOAc/hexanes) to give 10.84 g (44%) of Compound 10.



Compound 11

**Compound 11.** Compound 10 (11.88 g, 20.36 mmol) was dissolved in dioxane (200 mL) and aq lithium hydroxide (1.0 M, 400 mL) was added. The reaction mixture was stirred for 3 h then and partitioned between  $\text{CH}_2\text{Cl}_2$  and water. The organic layer was dried with  $\text{Na}_2\text{SO}_4$  and concentrated to give 9.34 g (99%) of Compound 11.




Compound VIII

**Compound VIII.** Compound 11 (0.63 g, 1.29 mmol) was dissolved in a mixture of  $\text{CH}_2\text{Cl}_2$  (60mL) and triethylamine (0.27 mL) and cooled in an ice bath. Triflic


anhydride (0.55 g, 1.95 mmol) was added and the reaction mixture was stirred for 1 h. The ice bath was removed, and the reaction mixture was stirred an additional 3 h. The reaction was partitioned between water and  $\text{CH}_2\text{Cl}_2$ . The organic layer was washed with water and dried with  $\text{Na}_2\text{SO}_4$ . The solvent was evaporated and the crude product was purified by sgc (20% EtOAc/hexanes) to give 0.53 g (66%) of Compound VIII.

Compound VIII :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 8.89-8.87 (m, 1H), 8.58 (d, 8Hz, 1H), 8.32-8.25 (m, 1H), 8.15-8.11 (m, 1H), 8.03-7.98 (m, 2H), 7.71-7.63 (m, 1H), 7.52-7.48 (m, 2H), 7.47-7.41 (m, 1H), 7.16-7.09 (m, 1H), 5.62 (d, 8 Hz, 1H), 4.90-4.80 (m, 1H), 1.63 (d, 7 Hz, 3H).

#### EXAMPLE V




Potassium hydroxide (3.1 g, 55.2 mmol), 2-bromo-4-chlorophenol (9.52 g, 45.9 mmol), and 4-fluorobenzonitrile (5.73 g, 47.3 mmol) were added to DMA (25 mL) and the reaction mixture was stirred between 100 °C and 110 °C for one week. The reaction mixture was stirred at rt an additional two days. The solvents were partially removed on the rotary evaporator and the resulting mixture was partitioned between water and a 3:1  $\text{Et}_2\text{O}$ /hexanes solution. The organic layer was washed with water and brine, then dried with  $\text{MgSO}_4$ . The solvents were evaporated and the crude product was purified by sgc (20%-30%  $\text{CH}_2\text{Cl}_2$ /hexanes) to give 11.96 g (81%) of an oil.



Compound 12


**Compound 12.** The product of the above step (5.90 g, 19.1 mmol) was placed under  $\text{N}_2$  atmosphere and a solution of borane in THF (1.0 M, 21 mL, 21 mmol) was

added causing an exotherm. Once the reaction mixture had returned to rt, it was heated to reflux and stirred at reflux overnight. Additional borane in THF (1.0 M, 20 mL, 20 mmol) was added and the reaction mixture was stirred at reflux for an additional 26 h then allowed to cool to rt. Water (55 mL) was added and the reaction mixture was partially concentrated. The resulting mixture was partitioned between EtOAc and aq NaOH (1.0 M). The organic layer was dried with MgSO<sub>4</sub> and concentrated to give 6.2 g of an oil. This material was dissolved in Et<sub>2</sub>O and a solution of HCl in Et<sub>2</sub>O was added causing Compound 12 (5.2 g, 78%) to precipitate as a solid.




Compound 13

**Compound 13.** Compound 12 (5.13 g, 16.6 mmol) was suspended in a mixture of CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and triethylamine (7.5 mL). The mixture was cooled in an ice-water bath and TFAA (2.35 mL, 16.6 mmol) was added. The reaction mixture was stirred for 1 h and 20 min and the ice bath was removed. The reaction mixture was stirred for an additional 1 h and 20 min at rt. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and washed with aq citric acid (0.5 M), saturated aq NaHCO<sub>3</sub>, water, and brine, then dried with MgSO<sub>4</sub>. The solvents were evaporated and the crude product (5.22 g) was purified *via* sgc (10%-20% EtOAc/hexanes gradient) to give Compound 13.




Compound 14

**Compound 14.** In a flame dried flask under N<sub>2</sub> blanket, Compound 13 (1.00 g, 2.47 mmol) was dissolved in anhyd THF (13 mL) and cooled in a dry ice/IPA bath. Methyllithium (1.4 M in Et<sub>2</sub>O, 2.3 mL, 3.22 mmol) was added, followed by n-BuLi (2.5 M in hexanes, 1.3 mL, 3.25 mmol). The reaction mixture was stirred for 1 h at -78 °C. A solution of 2,6-difluorobenzenesulfonyl fluoride (1.10 g, 5.60 mmol) dissolved in THF was added and the reaction mixture was stirred for 4 h. The reaction mixture was quenched with pH 7 sodium phosphate buffer (1.0 M) and EtOAc was added. The layers were separated and the aqueous layer was extracted with additional EtOAc. The combined organic layer was washed with brine and dried with MgSO<sub>4</sub>. The solvents were evaporated and the crude product was purified via sgc (20%-33% EtOAc/hexanes) gradient to give 76 mg of Compound 14.



Compound 15


**Compound 15.** Compound 14 (59 mg, 0.12 mmol) was dissolved in 700 µL of dioxane and LiOH (1.0 M, 300 µL, 0.3 mmol) was added. The reaction mixture was stirred at rt for 24 h then partitioned between CH<sub>2</sub>Cl<sub>2</sub> and 1.0 M aq NaOH. The organic layer was dried with MgSO<sub>4</sub> and concentrated. The crude product was purified via PTLC (Merck- silica plates, 3% (MeOH/NH<sub>3</sub>)/CH<sub>2</sub>Cl<sub>2</sub>) to give the desired Compound 15. (21 mg, 45%).




Compound IX

**Compound IX.** Compound 15 (17 mg, 0.042 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (166  $\mu\text{L}$ ) and DIPEA (20  $\mu\text{L}$ ). The flask was cooled in an ice/water bath and  $\text{MsCl}$  (12  $\mu\text{L}$ , 0.15 mmol) was added. The reaction mixture was stirred at 0 °C for 1 h and 30 min. The resulting mixture was partitioned between water and  $\text{CH}_2\text{Cl}_2$ . The organic layer was washed with water and brine, then dried with  $\text{MgSO}_4$ . The crude product was purified *via* PTLC (50 % EtOAc/hexanes) to give 10 mg (50%) Compound IX.

EXAMPLE VI



Compound 16



Compound X


**Compound 16** (0.116 g, 0.22 mmoles) was dissolved in  $\text{CH}_2\text{Cl}_2$  (4 mL) and cooled to 0 °C.  $\text{BBr}_3$  solution (1.0 M in  $\text{CH}_2\text{Cl}_2$ , 0.66 mL) was added and the ice bath was removed. The reaction mixture was stirred at rt for 48 h and then quenched with water at -78 °C. The reaction mixture was diluted with  $\text{CH}_2\text{Cl}_2$  and the resulting organic layer was washed with aqueous  $\text{NaHCO}_3$ ,  $\text{H}_2\text{O}$  (3 X 5 mL), and brine. The organics were dried over  $\text{Na}_2\text{SO}_4$  and the solvent was removed under vacuum to give 0.09 g of crude product. The product was isolated by PTLC (5%  $\text{CH}_3\text{OH}$  /  $\text{CH}_2\text{Cl}_2$ ) to provide Compound X (0.01g, 8.8%).



Compound 16 :  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ) 1.54 (d,  $J = 6.9\text{Hz}$  3H), 2.67 (s, 3H), 4.72 (q,  $J = 5\text{Hz}$  1H), 4.86 (br. d,  $J = 5\text{Hz}$ , 1H, NH), 7.08-8.42 (m, 11H).

5

EXAMPLE VII




10


Compound 17

**Compound 17** was converted to Compound 18 using the procedure in example VI.

15




Compound 18



Compound 19

**Compound 18** (0.34 g, 0.64 mmoles) was dissolved in DMF (11 mL), cesium carbonate (0.84 g, 2.58 mmol) was added and the reaction mixture was cooled to 15 °C. Dry bromodifluoromethane gas was introduced into the solution and bubbled for 15-20 min. Progress of the reaction was monitored by TLC and upon completion the reaction mixture was diluted with EtOAc (20 mL), washed with water (4 X 10 mL), and brine. The organics were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give 0.36 g of an oil. The crude product was purified by PTLC (50% EtOAc/hexanes) to provide 0.31 g (83%) of Compound 19.




Compound XI

**Compound 19** was converted to Compound XI using the procedure in example II.


**Compound XI** : <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) 1.51 (d, J = 7.2Hz 3H), 2.67 (s, 3H), 4.702 (q, J = 6.8Hz 1H), 5.05 (br. d, J = 6.4Hz, 1H, NH), 6.71 (t, J = 71.6 Hz, CF<sub>2</sub>H) 7.07-8.47 (m, 11H).

EXAMPLE VIII



Compound 20

**Compound 20.** To a solution of Compound 2 (5.00 g, 12.9 mmol) in anhyd THF (75 mL) at  $-78^{\circ}\text{C}$  was added *n*-BuLi (13 mL, 2.5 M in hexanes, 32 mmol) dropwise over 10 min. The reaction mixture was stirred for 30 min. A solution of di-*t*-butyl dicarbonate (3.10 g, 14.2 mmol) in anhyd THF (25 mL) was added in one portion via cannula. The reaction was allowed to proceed for 4 h at  $-78^{\circ}\text{C}$ . The reaction mixture was then diluted with EtOAc (~250 mL) and washed successively with saturated aq NaHSO<sub>4</sub> (~100 mL), water (~100 mL), and brine (~100 mL). The organic layer was dried over anhyd MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield a solid. Further purification of the solid by sgc (25% EtOAc/hexanes) gave 5.32 g (84%) of Compound 20 as a solid.




Compound XII

**Compound XII.** Compound 20 (2.06 g, 4.23 mmol) was dissolved in methanol (40 mL) and a solution of potassium carbonate (2.92 g, 21.1 mmol) in water (10 mL) was added. The reaction was allowed to proceed for 18 h. The solvent was then removed by evaporation under reduced pressure. The resulting white solid was partitioned between water (~100 mL) and EtOAc (~400 mL). The aqueous layer was extracted further with EtOAc (~100 mL). The combined organic layers were washed with brine (~500 mL), then dried over anhyd MgSO<sub>4</sub> and filtered. Evaporation of the


solvent gave 1.22 g (74%) of *t*-butyl 2-[(4-(1(*S*)-aminoethyl)phenyl)sulfonyl-5-methoxybenzoate, an oil, which was used in the next step without further purification. MsCl (242  $\mu$ L, 357 mg, 3.12 mmol) was added dropwise to a solution of crude *t*-butyl 2-[(4-(1(*S*)-aminoethyl)phenyl)sulfonyl-5-methoxybenzoate (1.22 g, 3.12 mmol) and triethylamine (522  $\mu$ L, 379 mg, 3.75 mmol) in anhyd  $\text{CH}_2\text{Cl}_2$  (3.0 mL) at 0  $^\circ\text{C}$ . The reaction mixture was stirred at 0  $^\circ\text{C}$  for 5 min, then allowed to warm to rt, and subsequently stirred for 3 h. The reaction mixture was diluted with  $\text{CH}_2\text{Cl}_2$  (~50 mL) and washed successively with 1 M HCl (~50 mL), water (3 x ~50 mL) and brine (~50 mL). The organic solution was dried over anhyd  $\text{MgSO}_4$ , filtered, and concentrated to yield a solid. Subsequent purification of the crude product by sgc (25% EtOAc/hexanes) gave 1.41 g (96%) of Compound XII as a solid.

#### EXAMPLE IX




Compound 21

**Compound 21.** In a flame dried flask under  $\text{N}_2$  blanket, Compound 5 (400 mg, 1.0 mmol) was dissolved in dry THF (5 mL) and cooled to  $-78\text{ }^\circ\text{C}$ . A solution of *n*-BuLi (1.0 M in hexanes, 1.9 mL, 1.9 mmol) was added and the reaction mixture was stirred for 30 min. 2-Fluorobenzaldehyde (200 mg, 1.6 mmol) was added and the reaction mixture was stirred at  $-78\text{ }^\circ\text{C}$  for 3 h. The reaction mixture was then quenched with saturated aq  $\text{NH}_4\text{Cl}$  (20 mL). Methylene chloride (30 mL) was added and the layers were separated. The organic layer was washed with brine, then dried over  $\text{Na}_2\text{SO}_4$ , and concentrated to dryness. The crude product was purified via sgc (25% EtOAc/hexanes) to give 330 mg (62%) of Compound 21 as a powder.



Compound 22


- 5 **Compound 22.** Compound 21 (10 mg) was dissolved in  $\text{CH}_2\text{Cl}_2$  (10 mL). Triethylsilane (40  $\mu\text{L}$ , 0.25 mmol) was added followed by  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  (20  $\mu\text{L}$ , 0.16 mmol). The reaction mixture was stirred at rt overnight. After removing the solvent, the crude product was purified via PTLC (25% EtOAc/hexanes) to give 6.0 mg (62%) Compound 22 as an oil.



Compound XIII


- 10 **Compound XIII.** Compound 22 (12 mg) was dissolved in methanol (2 mL) at rt.
- 15 NaOH (1.0 M, 2 mL, 2.0 mmol) was added and the mixture was stirred at rt for 2 h. The solvent was removed,  $\text{CH}_2\text{Cl}_2$  (15 mL) and brine (15 mL) were added, and the layers were separated. The aqueous layer was extracted with additional  $\text{CH}_2\text{Cl}_2$  (15 mL) and the combined organic layers were dried over  $\text{Na}_2\text{SO}_4$  and concentrated to dryness. The crude product was then dissolved in  $\text{CH}_2\text{Cl}_2$  (10 mL) and cooled to 0 °C.
- 20 MsCl (14  $\mu\text{L}$ , 0.18 mmol) was added followed by addition of pyridine (30  $\mu\text{L}$ , 0.37 mmol). The reaction mixture was slowly warmed to rt and stirred overnight. Brine (15 mL) was added and extracted. The organic layer was dried over  $\text{Na}_2\text{SO}_4$  and concentrated to dryness. The crude product was purified via PTLC (25% EtOAc/hexanes) to give 10 mg (86%) of Compound XIII as an oil.

EXAMPLE X



Compound 23


**Compound 23.** Compound 21 (330 mg, 0.64 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at rt. Celite (450 mg) was added followed by addition of PCC (450 mg, 2.1 mmol). The mixture was stirred at rt overnight. The solid was removed by filtration and the organic layer was washed with aq. NaHCO<sub>3</sub> and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was purified via sgc (33% EtOAc/hexanes) to give 310 mg (94%) of Compound 23 as a powder.



Compound XIV

**Compound XIV.** Compound 23 (15 mg) was dissolved in methanol (2 mL) at rt. NaOH (1.0 M, 2 mL, 2.0 mmol) was added and the mixture was stirred at rt for 2 h. The solvent was removed and CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and brine (15 mL) were added and the layers separated. The aq layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and the combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was then dissolved in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and cooled to 0 °C. MsCl (15 μL, 0.19 mmol) was added followed by addition of pyridine (30 μL, 0.37 mmol). The reaction mixture was slowly warmed to rt and stirred overnight. Brine (15 mL) was added and extracted. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to


dryness. The crude product was purified via PTLC (33% EtOAc/hexanes) to give 9 mg (62%) of Compound XIV as an oil.



5

Compound 24

**Compound 24.** Oven dried methyltriphenylphosphonium bromide (430 mg, 1.2 mmol) and LHDMS (1.0 M in hexanes, 1.8 mL, 1.8 mmol) were stirred in dry THF (5 ml) at 0 °C for 20 min., then warmed to rt and stirred for 10 min. A solution of Compound 23 (300 mg, 0.58 mmol) in THF (1 mL) was added dropwise. The mixture was stirred at rt overnight. EtOAc (20 ml) was added and the organic solution was washed with brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was purified via PTLC (25% EtOAc/hexanes) to give 260 mg (87%) of Compound 24 as an oil.



Compound XV

20


**Compound XV.** Compound 24 (200 mg, 0.39 mmol) was dissolved in methanol (3 mL) at rt. NaOH (1.0 M, 3 mL, 3.0 mmol) was added and the mixture was stirred at 50 °C for 2 h. The solvent was removed, CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and brine (20 mL) were added, and the layers were separated. The aqueous layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was then dissolved in CH<sub>2</sub>Cl<sub>2</sub>

25


(15 mL) and cooled to 0 °C. MsCl (200  $\mu$ L, 2.5 mmol) was added followed by addition of pyridine (400  $\mu$ L, 4.9 mmol). The reaction mixture was slowly warmed to rt and stirred overnight. Brine (15 mL) was added and the organic layer separated, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was purified via PTLC

5 (50% EtOAc/hexanes) to give 160 mg (82%) of Compound XV as an oil.

#### EXAMPLE XI



Compound 25




Compound 26

**Compound 26.** Compound 25 (1.3 g, 2.7 mmol) was stirred at rt with a mixture of CH<sub>2</sub>Cl<sub>2</sub>/TFA (2:1, 30 mL) for 3 h. The reaction mixture was then poured into brine (40 mL). The layers were separated. The aq layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 X 30 mL) and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (30 mL). EDCI (0.75 g, 3.9 mmol) and pentafluorophenol (0.73 g, 4.0 mmol) were added and the mixture was stirred at rt overnight. The reaction mixture was extracted with diluted aq NaOH and washed with brine. The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated



to dryness. The crude product was purified via sgc (33% EtOAc/hexanes) to give 1.15 g (72%) of Compound 26 as a foam.




5

Compound XVI

**Compound XVI.** Compound 26 (50 mg) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL). 1-Adamantanamine (21 mg, 0.14 mmol) was added followed by addition of DIPEA (0.05 mL, 0.29 mmol). The reaction mixture was shaken overnight. The reaction mixture was then subjected to Amberlyst 15 resin (300 mg, loading 4.1 mmol/g), and was again shaken overnight. The resin was removed by filtration. The filtrate was subjected to MP carbonate resin (Argonaut Technologies) (100 mg, loading 2.64 mmol/g) for 4 h. The resin was removed by filtration and the filtrate concentrated to give 33 mg (70%) of Compound XVI as a powder.

#### EXAMPLE XII




20

Compound 27

**Compound 27.** Compound 5 (500 mg, 1.3 mmol) was dissolved in dry THF (6 mL) at rt. NaH (53 mg, 60%, 1.3 mmol) was added, and the reaction mixture was stirred at rt for 1 h. The reaction mixture was then cooled to -78 °C, and n-BuLi (1.0


25

M in hexanes, 1.5 mL, 1.5 mmol) was added dropwise under N<sub>2</sub> atmosphere. The reaction was stirred at -78 °C for 40 min. A solution of I<sub>2</sub> (390 mg, 1.5 mmol) in THF (2 mL) was added dropwise. The reaction mixture was stirred at -78 °C for 3 h, then quenched with saturated aq NH<sub>4</sub>Cl (20 mL). EtOAc (30 mL) was added and the layers were separated. The organic layer was washed with brine, then dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness. The crude product (640 mg) was used without further purification. The crude product (60 mg) was dissolved in toluene (2 mL) and Pd(OAc)<sub>2</sub> (2 mg), P<sup>t</sup>Bu<sub>3</sub> (1 drop), NaO<sup>t</sup>Bu (14 mg, 0.15 mmol) and *p*-Chloroaniline (13 mg, 0.11 mmol) were added. The mixture was kept in a sealed tube and heated to 120 °C for 20 h. After cooling, methylene chloride (30 mL) and brine (20 mL) were added and the layers were separated. The organic layer was washed with brine, then dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness. The crude product was purified via PTLC (20% EtOAc/hexanes) to give 18 mg (30 %) of Compound 27 as a powder.




Compound XVII

**Compound XVII.** Compound 27 (12 mg) was dissolved in methanol (2 mL) at rt. NaOH (1.0 M, 2 mL, 2.0 mmol) was added and the mixture was stirred at rt for 3 h. The solvent was removed, CH<sub>2</sub>Cl<sub>2</sub> (20 mL) and brine (20 mL) were added, and the layers were separated. The aq layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was then dissolved in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and cooled to 0 °C. MsCl (15 μL, 0.19 mmol) and pyridine (30 μL, 0.37 mmol) were added. The reaction mixture was slowly warmed up to rt and stirred overnight. Brine (15 mL) was added and the reaction mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product was purified via PTLC (33% EtOAc/hexanes) to give 6.0 mg (52%) of Compound XVII as an oil.



### Compound 28


**Compound 28.** Compound 5 (500 mg, 1.3 mmol) was dissolved in dry THF (6 mL) at rt. NaH (53 mg, 60%, 1.3 mmol) was added, and the mixture was stirred at rt for 1 h. The reaction mixture was cooled to  $-78\text{ }^{\circ}\text{C}$ , and n-BuLi (1.0 M, 1.5 mL, 1.5 mmol) was added dropwise under  $\text{N}_2$  atmosphere, and the temperature was maintained at  $-78\text{ }^{\circ}\text{C}$  for 40 min. A solution of  $\text{I}_2$  (390 mg, 1.5 mmol) in THF (2 mL) was added dropwise. The reaction was stirred at  $-78\text{ }^{\circ}\text{C}$  for 3 h. The reaction mixture was quenched with saturated aq  $\text{NH}_4\text{Cl}$  (20 mL). EtOAc (30 mL) was added and the layers were separated. The organic layer was washed with brine, then dried over  $\text{Na}_2\text{SO}_4$ , and concentrated to dryness. The crude product (640 mg) was used without further purification. The crude product (60 mg) was dissolved in toluene (2 mL) and NaH (5 mg, 60%, 0.12 mmol),  $\text{CuBr}\cdot\text{Me}_2\text{S}$  (34 mg, 0.17 mmol) and *p*-chlorophenol (15 mg, 0.12 mmol) were added. The reaction mixture was kept in a sealed tube and heated to  $120\text{ }^{\circ}\text{C}$  overnight. After cooling,  $\text{CH}_2\text{Cl}_2$  (30 mL) and brine (20 mL) were added and the layers were separated. The organic layer was washed with brine, then dried over  $\text{Na}_2\text{SO}_4$ , and concentrated to dryness. The crude product was purified via PTLC (20% EtOAc/hexanes) to give 19 mg (31 %) of Compound 28 as a powder.



### Compound XVIII


**Compound XVIII.** Compound 28 (15 mg, 29  $\mu$ mol) was dissolved in methanol (2 mL) at rt. NaOH (1.0 M, 2 mL, 2.0 mmol) was added and the mixture was stirred at rt for 2 h. The solvent was removed and  $\text{CH}_2\text{Cl}_2$  (20 mL) and brine (20 mL) was added and the layers were separated. The aq layer was extracted with additional  $\text{CH}_2\text{Cl}_2$  (15 mL) and the combined organic layer was dried over  $\text{Na}_2\text{SO}_4$  and concentrated to dryness. The crude product was then dissolved in  $\text{CH}_2\text{Cl}_2$  (15 mL) and cooled to 0  $^\circ\text{C}$ . MsCl (20  $\mu$ L, 0.25 mmol) was added followed by addition of pyridine (20  $\mu$ L, 0.25 mmol). The reaction mixture was slowly warmed up to rt and stirred overnight. Brine (15 mL) was added and extracted with  $\text{CH}_2\text{Cl}_2$ . The organic layer was dried over  $\text{Na}_2\text{SO}_4$  and concentrated to dryness. The crude product was purified via PTLC (50% EtOAc/hexanes) to give 7.0 mg (48%) of Compound XVII as an oil.

EXAMPLE XIII




Compound 29

**Compound 29.** To a solution of N,N,N-Trimethylethylenediamine (1.2 mL, 8.6 mmol) in THF (8 mL) at -20  $^\circ\text{C}$  was added n-BuLi (1.6 M, 5.4 mL, 8.6 mmol) dropwise. After 15 min 4-trifluoromethoxybenzaldehyde (1.5 g, 7.8 mmol) in THF (8 mL) was added. The mixture was stirred for 15 minutes and additional n-BuLi (1.6M, 14.6 mL, 23 mmol) was added. The reaction mixture was stirred at -20  $^\circ\text{C}$  for 1h, then placed in the freezer at -20 $^\circ\text{C}$  for 20 h. The mixture was cooled to -40  $^\circ\text{C}$ , and a solution of bis(2-fluorophenyl)disulfide (4.0 g, 15.7 mmoles) in 30 mL THF was added. The reaction mixture was stirred at -35  $^\circ\text{C}$  for 3 h. The reaction mixture was poured into 0.5 N HCl and extracted with EtOAc. The organic layer was washed with water and brine, dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated to an oil. Purification by sgc (3 % EtOAc / hexanes) gave 1.55 g (62 %) of Compound 29 as a solid..




Compound 30

- 5 **Compound 30.** Methyllithium ( 3.25 mL, 5 mmol, 1.4 M ether) was added to a solution of Compound 1 ( 1.22 g, 4 mmol) at  $-70^{\circ}\text{C}$ . After 10 min n-BuLi (1.6 M in hexanes, 2.83 mL, 5 mmol) was added and stirred for 30 min. A solution of Compound 29 ( 1.44g, 4.55mmoles), dissolved in THF (15mL) was added. The resulting mixture was stirred at  $-70^{\circ}\text{C}$  for 2.5 h, quenched with water, warmed to  $0^{\circ}\text{C}$  and then
- 10 extracted with 2 X 50 mL EtOAc. The organic layer was washed with water, dried ( $\text{Na}_2\text{SO}_4$ ), filtered and concentrated to an oil. Purification by sgc (EtOAc : hexanes ) gave Compound 30 (1.4 g, 58%) as a gum.




Compound 31

- 15
- Compound 31.** Triethylsilane ( 3.5 mL, 22.5 mmol) was added to a solution of Compound 30 (0.6 g ,1.125 mmol) in  $\text{CH}_2\text{Cl}_2$  (30 mL), followed by addition of boron trifluoride etherate (0.32 mL, 1.94 mmol). After stirring at rt for 15 min the reaction mixture was diluted with 50 mL  $\text{CH}_2\text{Cl}_2$ , washed with water, dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated to give a solid. Purification via PTLC (25%EtOAc/hexanes
- 20 (1:3) gave Compound 31 (0.47 g, 89 %) as a solid.




Compound 32

**Compound 32.** MCPBA (1.56 g (56%), 5.09 mmol) was added to a solution of Compound 31 (0.47 g, 0.9 mmol) in  $\text{CH}_2\text{Cl}_2$  (30 mL) at rt. After stirring for 16 h the reaction was washed with 5% aq  $\text{NaHSO}_3$ , aq  $\text{NaHCO}_3$ , and water. The organics were dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated to give Compound 31 (0.4 g, 82%) as a solid.




Compound 33

**Compound 33.** 1 M aq  $\text{LiOH}$  (9.7 mL, 9.7 mmol) was added to a solution of Compound 32 (1.78 g, 3.2 mmol) in 1,4-dioxane (15 mL). The resulting mixture was stirred overnight. The solvent was removed under reduced pressure and the residue was dissolved in 50 mL  $\text{CH}_2\text{Cl}_2$  and washed with 10 mL brine. The organics were dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated to an oil, which was used in the next step without additional purification.



Compound 34


**Compound 34.** Triethylamine (0.28 mL, 2 mmol) was added to a solution of Compound 33 (0.18 g, 0.4 mmol) in  $\text{CH}_2\text{Cl}_2$  at rt, followed by addition of  $\text{MsCl}$  (0.061 mL, 7.9 mmol) in 0.2 mL  $\text{CH}_2\text{Cl}_2$ . The mixture was stirred overnight, then washed with 2 X 10 mL water, dried over  $\text{Na}_2\text{SO}_4$ , filtered, and concentrated to give an oil. The oil was purified via PTLC using EtOAc : hexanes (1:1) as the solvent to give Compound 34 (0.137g, 65%) as a solid.



Compound XIX


**Compound XIX.** Triethylamine (0.296 mL, 2.1 mmol) was added to a solution of Compound 33 (0.4 g, 0.9 mmol) in 8 mL of  $\text{CH}_2\text{Cl}_2$ , cooled to  $0^\circ\text{C}$ , followed by addition of a solution of trifluoromethanesulfonic anhydride (0.54 g, 1.9 mmol) in  $\text{CH}_2\text{Cl}_2$  (5 mL). The mixture was stirred at  $0^\circ\text{C}$  for 3 h, washed with water, dried over  $\text{Na}_2\text{SO}_4$ , filtered, concentrated under reduced pressure to give crude Compound XIX. The crude product was purified via PTLC using 33% EtOAc:hexanes to give Compound XIX as a solid (0.32 g, 62%).

EXAMPLE XIV



Compound XX


**Compound XX.** Triethylamine (0.018 mL, 0.129 mmol) was added to a solution of Compound 33 (0.05 g, 0.11 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) followed by addition of 4-(trifluoromethoxy)benzenesulfonyl chloride (0.02 mL, 0.118 mmol) in CH<sub>2</sub>Cl<sub>2</sub> at rt. The stirring was continued for 10 h. The reaction mixture was diluted with 50 mL CH<sub>2</sub>Cl<sub>2</sub>, washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude product was purified by PTLC (33%EtOAc: hexanes to give Compound XX as a solid (0.048 g, 65%).



Compound XXI

**Compound XXI.** Triethylamine (0.012 mL, 0.086 mmol) was added to a solution of Compound 33 (0.033 g, 0.073 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) at -5 °C. A solution of acetyl chloride (0.0057 mL, 0.08 mmol) in 0.5 mL CH<sub>2</sub>Cl<sub>2</sub> was added. The mixture was stirred overnight at rt. The organics were washed with water, and then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated under reduced pressure. The resulting crude was purified by PTLC (EtOAc) to provide Compound XXI as a solid (0.009 g, 25%).






Compound XXII

**Compound XXII.** Cyclopentyl isocyanate (0.0135 g, 0.12 mmol) was added as a  $\text{CH}_2\text{Cl}_2$  solution (0.5 mL) to a solution of Compound 33 (0.05 g, 0.11 mmol) in  $\text{CH}_2\text{Cl}_2$  (1 mL). The reaction mixture was stirred at rt overnight. The solvent was removed under reduced pressure and the crude product was subjected to PTLC (EtOAc/hexanes 1:2) to provide Compound XXII (0.04 g, 65%).


#### EXAMPLE XV



Compound XXIII


**Compound XXIII.** N-Boc-piperazine (0.5 g, 2.68 mmol) was added to a solution of Compound XIX (0.2 g, 0.34 mmol) in  $\text{CH}_3\text{CN}$  (10 mL). The reaction was heated at  $80^\circ\text{C}$  for 72 h. Additional N-Boc-piperazine (0.25 g, 1.34 mmol) was added and heated at  $80^\circ\text{C}$  for another 16 h. The solvent was removed under reduced pressure and the crude product was purified via PTLC (50%EtOAc:hexanes) to provide Compound XXIII as a solid, (0.096 g, 37%).

EXAMPLE XVI




Compound 35

**Compound 35.** Pyridinium chlorochromate (0.194 g, 0.899 mmol) was added to a mixture of Compound 30 (0.4 g, 0.75 mmol) and Celite (0.4 g) in  $\text{CH}_2\text{Cl}_2$  (10 mL) at rt. The mixture was stirred for 18 h, filtered through Celite and concentrated. The crude material was purified via PTLC using 33% EtOAc:hexanes to obtain Compound 35 (0.4 g, 100%).




Compound 36

**Compound 36.** MCPBA (1.29 g (56%), 4.18 mmol) was added to a solution of Compound 35 (0.4 g, 0.75 mmol) in  $\text{CH}_2\text{Cl}_2$  (20 mL) and stirred at rt for 18 h. The reaction was washed with 5% aq  $\text{NaHSO}_3$ , 5%  $\text{NaHCO}_3$ , and water. The organics were dried over  $\text{Na}_2\text{SO}_4$ , filtered and concentrated. The crude product was purified via PTLC using EtOAc:hexanes (1:1) to provide Compound 36 (0.34 g, 80%).




Compound 37

- 5      **Compound 37.** Compound 36 was converted to Compound 37 using a procedure similar to that described in example II.




Compound 38

10      **Compound 38.** LHMDs (0.9 mL, 1M solution THF, 0.896 mmol) was added to a suspension of methyltriphenylphosphonium bromide (0.215 g, 0.6 mmol) in anhydrous THF (10 mL) at 0 °C. The mixture was stirred at 0 °C for 20 min, then for  
15 10 minutes at rt. A solution of Compound 36 (0.17 g, 0.3 mmol) in THF (8mL) was added and stirring continued for 10 h at rt. The mixture was diluted with EtOAc and washed with water. The organics were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude product was purified via PTLC using EtOAc:hexanes (1:3) to provide Compound 38 as a solid. (0.09 g, 54%).



Compound XXIV


- 5 **Compound XXIV.** Compound 38 was converted to Compound XXIV using a procedure similar to that described in example II.



Compound XXV

- 10 **Compound XXV.** Hydroxylamine hydrochloride (0.076 g, 1.09 mmol) was added to a solution of Compound 37 (0.03 g, 0.055 mmol) in pyridine (0.5 mL). The mixture was heated at 80 °C for 24 h. The mixture was cooled to rt and the solvent was removed under reduced pressure. The residue was dissolved in 50 mL CH<sub>2</sub>Cl<sub>2</sub> and washed with water and brine. The organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to provide crude Compound XXV, which was purified via PTLC (EtOAc/hexanes, 1:3) to afford Compound XXV as a solid (0.01 g, 33%).


EXAMPLE XVII



5

Compound 39

**Compound 39.** In a flame dried flask under N<sub>2</sub> blanket, Compound 2 (4.00 g, 10.32 mmol) was dissolved in anhyd THF (41 mL) and cooled to -78°C. A solution of n-BuLi (2.5 M in hexanes, 8.25 mL, 20.6 mmol) was added and the reaction mixture was stirred for 25 min. Bis-4-chlorophenyl disulfide (3.10 g/ 10.8 mmol) was added and the reaction mixture was stirred at -78°C for 3 h then between -78 °C and -10°C for 3 h. The reaction mixture was quenched with pH 7.0 sodium phosphate buffer (1.0 M, 50 mL). The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with brine, then dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to dryness. The crude product (5.44 g foam) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (120 mL) and cooled to 0°C. MCPBA (7.24 g) was added. The ice bath was removed and the reaction mixture was stirred at rt overnight. Aqueous NaHCO<sub>3</sub> and CH<sub>2</sub>Cl<sub>2</sub> were added and the layers were separated. The organic layer was washed with aq NaHSO<sub>3</sub>, NaHCO<sub>3</sub>, H<sub>2</sub>O, and brine then dried with MgSO<sub>4</sub>. The crude product was purified by sgc (35%-40% EtOAc/hexanes gradient) to give 1.86 g (32%) of Compound 39.




Compound 40

25

**Compound 40.** Compound 39 (1.52 g, 2.70 mmol) was dissolved in dioxane (9 mL) and cooled to 0°C. LiOH (1.0 M aq, 3 mL, 3 mmol) was added and the reaction mixture was left stirring overnight, during which time it warmed to rt. The solvents were evaporated. CH<sub>2</sub>Cl<sub>2</sub> and aq NaOH were added and the layers were separated.


- 5 The aqueous layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> and the combined organic layer was dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated to give 0.85 g (68%) of Compound 40.



10  
Compound XXVI

**Compound XXVI.** Compound 40 (143 mg, 0.307 mmol) was dissolved in dioxane and sulfamide (0.128, 1.33 mmol) was added. The reaction mixture was stirred at reflux for 24 h then allowed to cool to rt and concentrated. The reaction mixture was purified via PTLC (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) giving 54 mg (32%) of Compound XXVI.


Example XVIII



20  
Compound 41


**Compound 41.** In a flame dried flask under N<sub>2</sub> blanket, 1-chloro-4-fluorobenzene (7.36 g, 56.4 mmol) was dissolved in anhyd THF and cooled in a dry ice/acetone bath. n-BuLi (2.5 M in hexanes, 22.5 mL, 56.3 mmol) was added and the

reaction was stirred for 50 min. 2-Fluorobenzene sulfonyl fluoride (10.3 g, 57.8 mmol) was added and the reaction mixture was left stirring overnight, during which time it warmed to rt. Saturated aq  $\text{NH}_4\text{Cl}$  (100 mL) was added, followed by EtOAc (100 mL) and the layers were separated. The organic layer was washed with water and brine, then dried with  $\text{MgSO}_4$ . The solvents were evaporated and the crude product was purified via sgc (10% EtOAc/hexanes) to afford Compound 41 (2.55 g, 16%) as a solid.




Compound 42

**Compound 42.** 4-Mercaptobenzoic acid (0.54 g, 3.50 mmol) was dissolved in DMA (10 mL) and cooled in an ice bath. Sodium hydride (60% suspension in oil, 0.30 g, 7.5 mmol) was added and the reaction mixture was stirred for 20 min. The ice bath was removed and the reaction mixture was stirred for 1 h. The flask was cooled to  $0^\circ\text{C}$  again and compound 41 (1.0 g, 3.46 mmol) dissolved in DMA (5 mL) was added. The reaction mixture was stirred at  $0^\circ\text{C}$  for 30 min, then allowed to warm to rt and stirred overnight. The reaction mixture was diluted with  $\text{CH}_2\text{Cl}_2$  and washed with 5% aq HCl, water, and brine. The organic layer was dried with  $\text{Na}_2\text{SO}_4$  and the solvents were evaporated. The crude product was purified via sgc (5% MeOH/ $\text{CH}_2\text{Cl}_2$ ) to give Compound 42 as a solid (1.04 g, 71%).



Compound 43


**Compound 43.** Pentafluorophenol (0.91 g, 4.94 mmol) and Compound 42 (1.04 g, 2.46 mmol) were dissolved in 30 mL of  $\text{CH}_2\text{Cl}_2$  and EDCI was added. The reaction was stirred overnight and diluted with water and  $\text{CH}_2\text{Cl}_2$ . The layers were separated and the organic layer was washed with water and dried with  $\text{Na}_2\text{SO}_4$ . The crude product was purified via sgc (5% EtOAc/hexanes) to give 0.9 g (62%) of Compound 43 as a solid.



Compound XXVII

**Compound XXVII.** Compound 43 (0.15 g, 0.25 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (5 mL). Morpholine (44 mg, 0.51 mmol) and DIPEA (49 mg, 0.38 mmol) were added and the reaction mixture was stirred at rt for 2h. The reaction mixture was diluted with EtOAc and washed with 5% aq  $\text{NaHCO}_3$ , water and brine. The organic layer was dried with  $\text{Na}_2\text{SO}_4$  and the solvents were evaporated. The crude product was purified via sgc (50% EtOAc/hexanes) to give 98 mg (77%) of Compound XXVII.






Compound XXVIII


**Compound XXVIII.** Compound XXXVII (72 mg, 0.146 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (3 mL) and MCPBA (ca 50%, 0.11 g, ca 0.36 mmol) was added. The reaction mixture was stirred overnight then diluted with  $\text{CH}_2\text{Cl}_2$ . The reaction mixture was washed with aq  $\text{Na}_2\text{CO}_3$  and water then dried with  $\text{Na}_2\text{SO}_4$ . The solvents were evaporated and the crude product was purified via sgc (60% EtOAc/hexanes) to give 61 mg (79%) of Compound XXXVIII as a solid.

Example XIX



Compound 44

**Compound 44.** Cyclopropyl benzene (48.5 g, 410 mmol), glacial acetic acid (510 mL), and sodium acetate (38.9 g, 474 mmol) were added to a roundbottomed flask. The flask was cooled in an ice-water bath. A solution of bromine (66.3 g, 414 mmol) dissolved in 105 mL of acetic acid was added dropwise over 90 min. The reaction mixture was stirred at temperatures between 0 °C and 10 °C for 5 h. The reaction was then allowed to warm to rt overnight. Hexanes (1300 mL) and water (250 mL) were added. Aqueous  $\text{NaHSO}_3$  (1M) was added until the reaction mixture changed from yellow to clear. The layers were separated. The organic layer was washed with water, 1M aq  $\text{Na}_2\text{CO}_3$ , and brine, then dried with  $\text{Na}_2\text{SO}_4$ . The solvent was evaporated and the crude product was purified *via* sgc using hexanes as the mobile phase to give 17 g of p-cyclopropylbromobenzene (21%) (Compound 44).



Compound 45


5

**Compound 45.** A flask was flame dried under N<sub>2</sub> blanket. Compound 44 (10.0 g, 50.7 mmol) was added, followed by dry THF (100 mL). The resulting solution was cooled to -78 °C. A solution of n-butyl lithium in hexanes (2.27 M, 22.35 mL, 50.7 mmol) was added dropwise *via* syringe. The reaction mixture was stirred for 10 min.

10 SO<sub>2</sub> gas was bubbled into the reaction mixture until the pH of a reaction mixture sample was <1 when mixed with water. The reaction mixture was stirred for 30 min at -78 °C. The ice bath was removed and the reaction mixture was allowed to warm to rt. The reaction mixture was stirred for an additional 30 min at rt. The reaction mixture was concentrated to afford a solid. CH<sub>2</sub>Cl<sub>2</sub> (500 mL) and N-

15 chlorosuccinamide (10.2 g, 76 mmol) were added and the reaction mixture was stirred for 4 hrs at rt. Water and CH<sub>2</sub>Cl<sub>2</sub> were added and the layers were separated. The organic layer was washed with water and brine, then dried with MgSO<sub>4</sub>. The solution was filtered and the solvents were evaporated to give 13.3 g of crude p-cyclopropylbenzenesulfonyl chloride (Compound 45).

20




Compound 46

25

**Compound 46.** Crude compound 45 (13.3 g) was dissolved in 200 mL of acetone and 60 mL of water. Potassium fluoride (7.12 g, 122 mmol) was added and the reaction mixture was stirred overnight at rt. The reaction mixture was diluted with EtOAc and washed with water. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and

concentrated to dryness to give 9.80 g (97%) of crude p-cyclopropyl benzenesulfonyl fluoride (Compound 46).

5




Compound 47

10

**Compound 47.** A flask was flame dried under N<sub>2</sub> blanket. Compound 1 (44.29 g, 150 mmol) was added, followed by 500 mL of anhydrous THF. The flask was cooled to -78 °C and a solution of n-butyl lithium in hexanes (1.77 M, 154 mL, 272 mmol) was added over 40 min. The reaction mixture was stirred for 1.5 h at -78 °C, then transferred *via* cannula into a solution of crude p-cyclopropylbenzenesulfonyl fluoride (27.2 g, 135 mmol) dissolved in 200 mL of anhydrous THF over 1.5 h. The reaction mixture was stirred for 1h. Water was added, followed by EtOAc. The layers were separated and the organic layer was washed with aq NH<sub>4</sub>Cl, water, and brine, then dried with Na<sub>2</sub>SO<sub>4</sub>. The solvents were evaporated, and the crude product was purified by sgc (25%-33% EtOAc/Hexanes gradient mobile phase) to give 24.5 g (45%) of compound 47.

20




25

Compound 48


**Compound 48.** A flask was flame dried under N<sub>2</sub> blanket. Compound 47 (16.33 g, 41.1 mmol) was dissolved in 400 mL of anhydrous THF and cooled to -78

°C. A solution of n-butyl lithium in hexanes (2.3 M, 35.7 mL, 82.1 mmol) was added dropwise *via* syringe. The reaction mixture was stirred for 1.5 h at -78 °C. A solution of 2, 2'-dithiodipyridine (8.89 g, 41.1 mmol) dissolved in 40 mL of THF was added and the reaction mixture was stirred for 2 h. The cold bath was removed, and the reaction mixture was allowed to warm to rt overnight. The reaction mixture was cooled with an ice-water bath and the reaction was quenched with 10 mL of water. The reaction mixture was diluted with EtOAc and washed with saturated aq NH<sub>4</sub>Cl, water, and brine. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated. The crude product was purified via sgc using 1:2 EtOAc/Hexanes as the mobile phase giving 15.49 g (74%) of Compound 48.




Compound 49

**Compound 49.** Compound 48 (15.49 g, 30.6 mmol) was dissolved in 1 L of CH<sub>2</sub>Cl<sub>2</sub> and the flask was placed in a rt water bath. MCPBA (22.0 g, ca 74 mmol) was added in portions and the reaction mixture was left stirring overnight at rt. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with 10% aq NaHCO<sub>3</sub>, water, and brine, then dried with Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated and the crude product was purified *via* sgc using a 20%-50% EtOAc/Hexanes gradient as the mobile phase. Compound 49 (9.4 g, 57%) was isolated as a solid.



Compound 50


**Compound 50.** Compound 49 (10.16 g, 18.87 mmol) was dissolved in 300 mL of p-dioxane and 300 mL of 1.0 M aq LiOH was added. The reaction mixture was stirred at rt for 3 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub>. The layers were separated, and the organic layer was washed with water and brine, then dried with Na<sub>2</sub>SO<sub>4</sub>. The solvents were evaporated to give 9.0 g of crude Compound 50.



Compound XXIX

**Compound XXIX.** Crude compound 50 (7.74 g, 17.5 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL). Diisopropylethylamine (2.71 g, 21 mmol) was added and the flask was cooled to -78 °C. A solution of triflic anhydride (5.97 g, 21.1 mmol) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50mL) was added dropwise over 1h. The reaction mixture was stirred for 2 h at -78 °C. The cold bath was removed, and the reaction mixture was allowed to warm to rt overnight. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with water and brine. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub> and the solvents were evaporated. The crude product was purified *via* sgc using 1:2 EtOAc/Hexanes as the mobile phase to give 8.61 g (85%) of Compound XXIX.


Compound XXIX: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.56-8.52 (m, 1H), 8.32-8.21 (m, 3H), 8.02-7.92 (m, 4H), 5.42 (d, 9 Hz, 1H), 8.02-7.92 (m, 4H), 5.42 (d, 1H, 9 Hz), 4.84-4.78 (m, 1H), 2.16-2.06 (m, 1H), 1.60 (d, 7Hz, 3H), 1.20-1.17 (m, 2H), 0.97-0.89 (m, 1H).



Compound XXX

5 **Compound XXX.** Compound XXX was prepared from compound 47 using the procedures in example II.


Compound XXX:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.33-8.22 (m, 3H), 8.00-7.94 (m, 2H), 7.66-7.58 (m, 1H), 7.53-7.37 (m, 4H), 7.16-7.05 (m, 1H), 5.160 (d, 9 Hz, 1H), 4.88-4.83 (m, 1H), 2.17-2.06 (m, 1H), 1.65 (d, 7 Hz, 3H), 1.28-1.20 (m, 2H), 0.97-0.90 (m, 2H).



Compound XXXI


15 **Compound XXXI.** The potassium salt of compound XXIX (56 mg, 0.09 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (5 mL) and  $\text{Na}_2\text{HPO}_4$  (0.13 g, 0.91 mmol), and urea-hydrogen peroxide complex (85 mg, 0.90 mmol) were added. Trifluoroacetic acid was added (47 mg, 0.22 mmol) and the reaction mixture was refluxed for 4 h then left stirring overnight at rt. Additional urea-hydrogen peroxide complex (85 mg, 0.9 mmol) and TFAA (0.56 mmol) were added and the reaction mixture was refluxed for 6h. The reaction mixture was allowed to cool to rt and diluted with  $\text{CH}_2\text{Cl}_2$  and water. The layers were separated and the organic layer was washed with water, dried with  $\text{Na}_2\text{SO}_4$ , and concentrated. The crude product was purified *via* PTLC on silica using EtOAc as the mobile phase to give 34 mg (64%) of compound XXXI.

Compound XXXI:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.38-8.29 (m, 2H), 8.17 (d, 8 Hz, 1H), 8.07-8.02 (m, 1H), 7.91-7.85 (m, 2H), 7.56-7.36 (m, 5H), 6.11 (d, 8 Hz, 1H), 4.84-4.78 (m, 1H), 2.12-2.01 (m, 1H), 1.57 (d, 7Hz, 3H), 1.21-1.12 (m, 2H), 0.92-0.86 (m, 2H).



Compound XXXII


**Compound XXXII.** Compound V (0.50 g, 0.85 mmol), zinc (II) cyanide (65 mg, 0.55 mmol), zinc dust (11 mg, 0.17 mmol), 1,1'-Bis(diphenylphosphino)ferrocene (21 mg, 0.04 mmol), and tris(dibenzylideneacetone) dipalladium (17 mg, 0.129 mmol) were added to a 25 mL flask. Dimethylacetamide was added and the reaction mixture was placed under  $\text{N}_2$  blanket and heated to 110  $^\circ\text{C}$ . The reaction mixture was stirred at 110  $^\circ\text{C}$  for 4 h, then partitioned between EtOAc and water. The organic layer was washed with 2M ammonium hydroxide, water, and brine, then dried with  $\text{MgSO}_4$ . Evaporation of the solvent afforded 0.49 g of an oil that was purified *via* sgc using a 20%-25% EtOAc/Hexanes gradient mobile phase to afford compound XXXII (0.20 g).



Compound XXXIII

**Compound XXXIII.** Compound V (0.51 g, 0.87 mmol), tris(dibenzylideneacetone) dipalladium (40 mg, 0.04 mmol), 2-(dicyclohexylphosphino)-


biphenyl (36 mg, 0.103 mmol), and sodium tert-butoxide (204 mg, 2.12 mmol) were added to a Schlenk flask under N<sub>2</sub> blanket. Toluene (2.5 mL) was added, followed by benzophenone imine (210 mg, 1.15 mmol). The reaction mixture was stirred overnight at 70 °C under N<sub>2</sub>. The reaction mixture was allowed to cool to rt and 1 M aq HCl was added. The reaction mixture was diluted with EtOAc and the layers were separated. The organic layer was washed with water and brine, then dried with MgSO<sub>4</sub>. The resulting material was filtered and concentrated to give 0.37 g of an oil. The crude product was purified *via* sgc using a 25%-50% EtOAc/Hexanes gradient mobile phase, followed by a 5%MeOH/45%EtOAc/50%Hexanes mobile phase to give 0.11 g of an oil as product.



Compound XXXIV

**Compound XXXIV.** Compound V (264 mg, 0.45 mmol), sodium tert-butoxide (103 mg, 1.07 mmol), tris(dibenzylideneacetone) dipalladium (107 mg, 0.116 mmol), and 2-(di-tert-butyl-phosphino)biphenyl (61 mg, 0.20 mmol) were added to a Schlenk flask under N<sub>2</sub>. THF (1.5 mL) and cyclopropylamine (0.6 g, 10.5 mmol) were added and the reaction mixture was stirred for 24 h at rt. EtOAc and 1 M aq HCl were added and the layers were separated. The organic layer was washed with 1 M aq HCl, water, and brine, then dried with MgSO<sub>4</sub>. Filtration and evaporation of the solvents gave an oil which was purified *via* sgc using 25% EtOAc/Hexanes as the mobile phase. Compound XXIV (109 mg) was obtained as a foam.






**Compound XXXV**

5 **Compound XXXV.** Compound XXXV was prepared from compound 5 according to the procedures in Example XIX.


Compound XXXV:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.88 (d, 1.2 Hz, 1H), 8.51-8.56 (m, 2H), 8.31 (dd, 8 Hz, 1 Hz, 1H), 8.18 (dd, 8 Hz, 1 Hz, 1H), 8.08-7.96 (m, 3H), 7.62-7.48 (m, 3H), 5.51 (d, 9Hz, 1H), 4.90-4.70 (m, 1H), 1.62 (d, 7 Hz, 3H).



**Compound XXXVI**


**Compound XXXVI.** Compound XXXVI was prepared from compound XXXV according to the procedure in Example XIX.

Compound XXXVI:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  10.19 (d, 7.8 Hz, 1H), 8.27-8.42 (m, 4H), 8.13 (dd, 7.8 Hz, 2.1 Hz, 1H), 7.93 (d, 8.4 Hz, 2H), 7.78-7.63 (m, 2H), 7.59 (d, 8.4 Hz, 2H), 4.80 (m, 1H), 1.44 (d, 6.9 Hz, 3H).




Compound XXXVII

**Compound XXXVII.** Compound XXXV (0.312 g, 0.548 mmol) was dissolved in 2 propanol (20 mL) and 1.0 M aq NaOH was added (10 mL). The reaction mixture was stirred at temperatures between 80 °C to 84 °C for six days. The reaction mixture was allowed to cool to rt and partially concentrated. EtOAc was added and the layers were separated. The aqueous layer was acidified with 1 M aq H<sub>2</sub>SO<sub>4</sub> and extracted with EtOAc. The combined organic layer was dried with MgSO<sub>4</sub> and concentrated to give 0.29 g of an oil. The crude product was purified via sgc using a 25%-33% EtOAc/Hexanes gradient as the mobile phase. The fraction containing Compound XXVII was repurified via sgc using 3% MeOH/CH<sub>2</sub>Cl<sub>2</sub> as the mobile phase to give 0.05 g (15%) of Compound XXXVII as a solid.




Compound XXXVIII

**Compound XXXVIII.** Compound XXXVIII was prepared from compound XXXV according to the procedure used to prepare compound XXXII.




Compound XXXIX

**Compound XXXIX.** Compound XXXII (0.10 g, 0.17 mmol) was dissolved in acetone (1.5 mL) and water (1 mL). Potassium carbonate (3 mg, 0.022 mmol) and urea-hydrogen peroxide complex (0.16 g, 1.70 mmol) were added and the reaction mixture was stirred overnight at rt. The reaction mixture was diluted with EtOAc and washed with water. The solvents were evaporated and the crude product was purified via PTLC on SiO<sub>2</sub> using 50% EtOAc/Hexanes as the mobile phase to afford Compound XXXIX (75 mg, 73%) as a solid.




Compound XXXX

**Compound XXXX.** Compound XXXX was prepared from compound 2 according to the procedures in Example II.




Compound XXXXI

**Compound XXXXI.** Compound XXXXI was prepared from compound XXXX according to the procedure used to convert compound 16 to compound X.



Compound XXXXII


**Compound XXXXII.** Compound XXXXI (0.15 g, 0.264 mmol) was dissolved in DMA (5 mL). Potassium iodide (0.22 g, 1.30 mmol), cesium carbonate (0.19 g, 0.58 mmol), and 2-bromopropane (49 mg, 0.398 mmol) were added and the reaction mixture was left stirring at rt over the weekend. EtOAc was added and the reaction mixture was washed with satd. aq  $\text{NH}_4\text{Cl}$  and water. The organic layer was dried with  $\text{Na}_2\text{SO}_4$  and concentrated. The crude product was purified *via* sgc using 3%  $\text{Et}_2\text{O}/\text{CH}_2\text{Cl}_2$  as the mobile phase to give 83 mg (51%) of Compound XXXXII.



Compound XXXXIII

**Compound XXXXIII.** Compound XXXXI (0.10 g, 0.176 mmol) was dissolved in DMF (2 mL). Sodium hydride (7 mg, *ca* 1.2 eq) and bromomethylcyclopropane (26 mg, 0.19 mmol) were added and the reaction was stirred at 50 °C for 4 hr then allowed to cool to rt. EtOAc and water were added, and the layers were separated. The organic layer was washed with water and dried with  $\text{Na}_2\text{SO}_4$ . The solvent was

evaporated and the crude product was purified via sgc using 33% EtOAc/Hexanes as the mobile phase to give 15 mg (14%) of Compound XXXXIII.




5

Compound XXXXIV

**Compound XXXXIV.** Compound XXXXIV was prepared according to the procedure used for Compound XXXXIII using ethyl iodide as the electrophile and stirring the reaction at rt overnight before workup.

10




15

Compound XXXXV

**Compound XXXXV.** Compound XXXXI (0.40 g, 0.70 mmol) was dissolved in DMF (8 mL) and NaH (62 mg, ca 2.2 eq) was added. The reaction mixture was stirred for 30 min. Sodium iodide (0.52 g, 3.46 mmol) and 2-chloroethyl methyl ether (80 mg, 0.85 mmol) were added. The reaction mixture was stirred for 1 h at rt then 5 h at 110 °C. The reaction mixture was allowed to cool to rt. EtOAc and satd aq NH<sub>4</sub>Cl were added and the layers were separated. The organic layer was washed with water and dried with Na<sub>2</sub>SO<sub>4</sub>. Evaporation of the solvent, followed by sgc using 50% EtOAc/Hexanes as the mobile phase, afforded 0.21 g (48%) of Compound XXXXV.


20

25




Compound XXXXVI

5        **Compound XXXXVI.** Compound 50 (50 mg, 0.11 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (3 mL) and acetic acid (7 mg). Acetone (6 mg, 0.13 mmol), and  $\text{NaBH}(\text{OAc})_3$  (36 mg, 0.169) were added, and the reaction mixture was left stirring at rt overnight. EtOAc was added and the reaction mixture was washed with 10%  $\text{Na}_2\text{CO}_3$  and water. The solvents were evaporated and the crude product was purified via PTLC on  $\text{SiO}_2$  using EtOAc as the mobile phase. The resulting product was dissolved in EtOAc and HCl in  $\text{Et}_2\text{O}$  was added causing a white precipitate to form. The solvent was removed and the precipitate was washed with  $\text{Et}_2\text{O}$  and dried *in vacuo* to give 32 mg (49%) of compound XXXXVI as a solid.



Compound XXXXVII


20        **Compound XXXXVII.** Compound XXXXVII was prepared according to the procedure used for compound XXXXVI using cyclopentanone as the carbonyl source.



Compound XXXXVIII

5

**Compound XXXXVIII.** Compound XXXXVIII was prepared according to the procedure used for compound XXXXVI using cyclohexanone as the carbonyl source.




Compound XXXXIX

10

**Compound XXXXIX.** Compound XXXXIX was prepared according to the procedure used for compound XXXXVI using cyclopropanecarboxaldehyde as the carbonyl source.


20



Compound XXXXX


25

**Compound XXXXX.** Compound XXVIII (0.10 g, 0.197 mmol) was dissolved in a solution of borane in THF (1.0 M, 1.0 mL, 1.0 mmol). The reaction mixture was refluxed for 4 h then allowed to cool to rt. The solution was concentrated. Methanol (5 mL) and 1 M aq HCl (5 mL) were added and the resulting solution was stirred for 5 h at rt. The reaction mixture was concentrated and EtOAc was added. The resulting solution was washed with aq NaOH and water, then dried with Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated and the crude product was purified via PTLC using 40% EtOAc/Hexanes as the mobile phase. The product isolated from this step was dissolved in EtOAc, and HCl in Et<sub>2</sub>O was added causing a precipitate to form. The solvent was removed and the precipitate was washed with Et<sub>2</sub>O and dried *in vacuo* to give 22 mg (21%) of Compound XXXXX as a solid.



Compound 51


Compound 51 was prepared from Compound 2 according to the procedures in Example 11.



Compound XXXXXI

**Compound XXXXXI.** Compound XXXXXI was prepared from compound 51 according to the procedure used to prepare compound XXXXVI.






5

Compound XXXXXII

**Compound XXXXXII.** Compound XXXXXII was prepared from compound 51 according to the procedure used to prepare compound XXXXVI using 3-methyl-2-thiophenecarboxaldehyde as the carbonyl source.

10




Compound XXXXXIII

15

**Compound XXXXXIII.** Compound XXXXXIII was prepared from compound 51 according to the procedure used to prepare compound XXXXVI using benzaldehyde as the carbonyl source.


20



25


Compound 52

**Compound 52.** Compound 52 was prepared from compound 2 using the procedures in Example II with benzenesulfonyl fluoride as the initial electrophile.



Compound XXXXXIV


**Compound XXXXXIV.** Compound 52 (0.29 g, 0.67 mmol), cesium carbonate (0.44 g, 1.35 mmol), tris(dibenzylideneacetone) dipalladium (31 mg, 0.034 mmol), dppp (28 mg, 0.068 mmol), and 2-bromopyridine (0.16 g, 1.01 mmol) were dissolved in 11 mL of toluene under N<sub>2</sub> blanket. The reaction mixture was stirred at 80 °C overnight under N<sub>2</sub>, then allowed to cool to rt. CH<sub>2</sub>Cl<sub>2</sub> was added and the reaction mixture was washed with 2M aq NaHCO<sub>3</sub>, water, and brine. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub> and the solvent was evaporated. The crude product was purified *via* sgc using EtOAc as the mobile phase. The resulting material was dissolved in EtOAc and a solution of HCl/Et<sub>2</sub>O was added. The solvents were evaporated to give 145 mg (42%) of Compound XXXXXIV as a solid.



Compound XXXXXV

**Compound XXXXXV.** Compound XXXV (0.92 g, 1.67 mmol), was dissolved in methanol (40 mL) and 1.0 M aq NaOH was added (20 mL). The reaction mixture was stirred at 70 °C for 21 h. The reaction mixture was concentrated and extracted with EtOAc. The organic layer was washed with 1 M aq HCl, water, and brine, then dried with MgSO<sub>4</sub>. The solvent was evaporated and the crude product was purified via sgc using 25%-33% EtOAc/Hexanes as the mobile phase. Compound XXXXXV (0.82 g, 90%) was isolated as an oil.


Compound XXXXV: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.56 (d, 3.9 Hz, 1H), 8.31-8.22 (m, 2H), 8.124 (d, 2.7 Hz, 1H), 8.05-7.95 (m, 1H), 7.92 (d, 8.4 Hz, 2H), 7.750-7.45 (m, 1H), 7.92 (d, 8.4 Hz, 2H), 7.27-7.23 (m, 2H), 5.8 (d, NH, 1H), 4.85-4.75 (m, 1H), 3.99 (s, 3H), 1.58 (d, 7.2 Hz, 3H).



Compound XXXXXVI

**Compound XXXXXVI.** Compound 50 was converted to compound XXXXXVI according to the procedure in Example II.


Compound XXXXXVI: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 8.56-8.52 (m, 1H), 8.31-8.23 (m, 3H), 8.02-7.90 (m, 4H), 4.87-4.78 (d, 7 Hz, 1H), 4.69 (m, 1H), 2.66 (s, 3H), 2.16-2.06 (m, 1H), 1.51 (d, 7 Hz, 3H), 1.27 -1.17 (m, 2H), 0.96-0.90 (m, 2H).



Compound 53


**Compound 53.** 2-fluoro-4-chloroaniline (22.90 g, 151 mmol) was dissolved in 120 mL of AcOH and 80 mL of concentrated HCl was added with stirring. The

reaction mixture was cooled to 0 °C and a solution of NaNO<sub>2</sub> (27.2 g, 0.4 mol) dissolved in 40 mL of H<sub>2</sub>O was added over 10 min. The reaction mixture was stirred for 30 min at 0 °C. In a separate flask, 500 mg of CuCl was dissolved in 200 mL of AcOH. The flask was cooled to 0 °C and SO<sub>2</sub> gas was bubbled into the solution for 40 minutes. The contents of the "aniline" flask were added to the contents of the second flask over 20 minutes causing a vigorous evolution of gas. After the addition was complete, the ice bath was removed, and the reaction mixture was allowed to warm to rt. The reaction mixture was poured into 500 g of chipped ice and the resulting solids were collected, washed and dried to give 26.1 g (73%) of compound 53.




Compound 54

**Compound 54.** Compound 53 (4.0 g, 17.5 mmol) was dissolved in acetone (80 mL) and a solution of potassium fluoride (2.03 g, 35 mmol) in water (40 mL) was added. The reaction mixture was stirred at rt overnight. It was partially concentrated on the rotovap, then partitioned between CH<sub>2</sub>Cl<sub>2</sub> and water. Evaporation of the solvent afforded Compound 54 (2.60 g, 70%) as an oil.




Compound 55

**Compound 55.** Compound 55 was prepared from α-methyl benzylamine using a procedure similar to that used to prepare compound 1. N-Iodosuccinamide was substituted for DBDMH and the product was recrystallized from isopropanol/water.




Compound 56

**Compound 56.** Compound 55 (4.33g, 12.5 mmol) was dissolved in THF (50 mL) and TMEDA (5.6 mL, 37 mmol) was added. The flask was placed under N<sub>2</sub> blanket and cooled to 0 °C. A solution of isopropyl magnesium chloride (2.0 M in THF, 15 mL, 30 mmol) was added via syringe over 6 min. The reaction mixture was stirred at 0 °C for 1 h. The resulting solution was transferred via cannula into a flask containing compound 53 (15 mmol) in an ice-water bath over 15 min. The reaction mixture was left stirring at 0 °C for 1.5 h. Aq NH<sub>4</sub>Cl was added and the reaction mixture was extracted with EtOAc. The combined organic layer was washed with brine and dried with MgSO<sub>4</sub>. The solvents were evaporated and the crude product was purified via sgc using 1:4 EtOAc/Hexanes as the mobile phase. Solid compound 56 (3.5 g, 68%) was obtained.



Compound 57


**Compound 57.** Compound 56 was converted to compound 57 using hydrolysis and sulfonylation procedures similar to those described in Example II.



Compound 58

**Compound 58.** Compound 57 (0.10g, 0.22 mmol) was dissolved in 1 mL of dioxane and 2-mercaptoimidazole was added (28 mg, 0.28 mmol). Sodium hydride (60% dispersion in mineral oil, 18 mg) was added and the reaction mixture was stirred at 100 °C for 8 h. The reaction mixture was quenched with ice and extracted with

5 EtOAc. The organic layer was dried with MgSO<sub>4</sub> and the solvents were evaporated. The crude product was purified via sgc using a 5:95 MeOH/CH<sub>2</sub>Cl<sub>2</sub> mobile phase to give 18 mg (15%) of compound 58 as product.



Compound XXXXXVII

**Compound XXXXXVII.** Compound 57 was oxidized to compound XXXXXVII

15 using a procedure similar to that used to oxidize Compound XIX to compound XXI.

It will be understood that various modifications may be made to the embodiments and examples disclosed herein. Therefore, the above description

20 should not be construed as limiting, but merely as exemplifications of preferred embodiments. Those skilled in the art will envision various modifications within the pe and spirit of the claims appended hereto.